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I can guess you guys are not ready for that yet... 
but your kids are gonna love it! 
(Marty McFly, Back to the future) 
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Carrier systems for drug delivery 
 
Introduction 
 
In the past decades a significant advancement has been made in our 
understanding of cancer biology. Anyway, cancer still remain one of the 
major causes of death in the world, and one of the main reasons for this 
is our inability to selectively deliver therapeutics at their own sites of 
action without affecting healthy tissues[1]. 
Moreover, in order for an active compound to show its biological 
activity, it is necessary to reach the therapeutic concentration inside the 
cell: this is possible only if the molecule is able to pass through 
biological barriers. 
Many drug candidates have little effect because of a poor barrier 
permeation, a poor pharmacokinetic profile or because they are 
substrates for efflux proteins[2]. 
Most of the drug which can cross cell membranes and physiological 
barriers are both small and lipid-soluble molecules, according to the 
Lipinski's rule-of-five. However, most drug candidates lack this 
physicochemical characteristics. 
Some approaches have been developed to enable drugs to cross 
membranes: 
 modifying the structure to increase the permeability by passive 
diffusion (e.g., prodrug approaches improving drug lipophilicity 
or with chemical delivery systems); 
 blocking efflux transport systems; 
 prodrug approach consisting in the conjugation of a drug to a 
vector, which is a ligand of a transporter or a receptor on the 
surface of the barrier; 
 nanotechnology-based systems: colloidal drug carriers that 
permit the ideally targeted delivery of drugs dissolved, 
entrapped, encapsulated inside the core or adsorbed or 
chemically conjugated to their surface. 
All these requirements can be well satisfied by biocompatible and 
biodegradable nanoparticles[3].  
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Nanoparticles 
 
Following the IUPAC definition, we can define a nanoparticle as: 
 "a particle of any shape with dimensions in the 1x10-9 
and  1x10-7 m range. [...] Note 2: The basis of the 100-
nm limit is the fact that novel properties that 
differentiate particles from the bulk material typically 
develop at a critical length scale of under 100 nm. Note 3: 
Because other phenomena transparency or turbidity, 
ultrafiltration, stable dispersion, etc.) that extend the 
upper limit are occasionally considered, the use of the 
prefix nano is accepted for dimensions smaller than 500 
nm"[4]. 
Many kinds of nanoparticles are currently used in biomedical research 
and drug discovery[5]: 
 
 Inorganic nanoparticles: their core can be composed of silica, 
alumina, metals, metal oxides, metal sulfides and they vary in 
size, shape and porosity. Inorganic nanoparticles may be 
engineered to evade the reticuloendothelial system by varying 
size and surface composition; moreover, they may be porous, 
thus providing a physical encasement to protect a molecule by 
degradation. 
 
 Polymeric nanoparticles: they are tyically composed by a 
polymer, such as poly(ethylene glycol) (PEG), polylactic acid, 
polyglycolic acid, poly(methylmethacrilate), poly (butyl)cyano 
acrilate, polylactide (PLA) and poly(-lactide-co-glycolide) 
(PLGA)[6][7][8]. These polymers can be formulated to encapsule 
several classes of therapeutic agents. They also show a good 
potential for surface modifications: in fact, since nanoparticles 
come into direct contact with cellular membranes, their surface 
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properties may determine the mechanism of internalization and 
intracellular localization. 
 
 Solid lipid nanoparticles: they are lipid-based colloidal carriers, 
initially designed as an alternative to liposomes. In fact, they are 
more stable  in biological systems due to their relatively rigid 
core, consisting of hydrophobic lipids that are solid at room and 
body temperature, surrounded by a monolayer of phospholipids.  
These aggregates are further stabilized by high levels of 
surfactants, that contribute to the release profile of the drug. 
 
 Liposomes: they are concentric bilayered vesicles with an 
aqueous nucleus surrounded by a phospholipid membrane. 
Thanks to their amphiphilic nature, their ease of surface 
modification and their good bicompatibility they constitute a 
promising solution for increasing the circulating half-life of 
proteins and peptides. Liposomes can be designed to adhere to 
cellular membranes to deliver a drug but, unfortunately, they 
suffer for a low biological stability. 
 
 Nanocrystals: they are aggregates of molecules that can be 
combined into a crystalline form in which the drug is 
surrounded by a thin coating of surfactant. One of the most 
important applications of these systems is as quantum dots for 
biological imaging. 
This kind of formulation allows to increase the bioavailability  of 
poorly soluble drugs, but has as a drawback a limited stability of 
nanocrystals and the fact that crystallization is required and 
some therapeutics are not easily crystallized. 
 
 Nanotubes: self-assembling sheets of atoms arranged in tubes, 
with large internal volumes and an external surface that can be 
easily functionalized. The most popular version involves the use 
of soluble fullerene derivatives. Even if potentially promising, 
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human tolerance and toxicity of these compounds still remains 
unknown. 
 
 Dendrimers: polymeric-based macromolecules formed from 
monomeric or oligomeric units such that each layer doubles or 
triples the number of peripheral groups. They generally have a 
symmetrical structure, with the possibility to create an isolated 
"active site" core area through chemical functionalization. Thus, 
water-soluble dendrimers may be designed with internal 
hydrophobicity, suitable for the incorporation of a hydrophobic 
drug. 
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Mechanisms for cellular targeting 
 
Passive targeting: EPR effect 
 
Most solid tumors possess some characteristics that are not observed in 
healthy tissues such as: 
 
 an extensive angiogenesis (hypervasculature); 
 abnormal gaps the blood vessels cells: in fact, normal 
vasculature is impermeable to molecules larger than 2-4 nm, 
while tumor tissues are permeable to molecules with a diameter 
up to 600 nm; 
 a poor lymphatic drainage system, that results in a decreased 
clearance of the nanocarriers from the tumor site; 
 expression of a great number of permeability mediators. 
 
These characteristics result is known as enhanced permeability and 
retention (EPR) effect. This effect allows nanoparticles to extravasate 
and accumulate in the tumor tissues and it is also known as passive 
tumor targeting[8][9] (Figure 1). 
Thus, passive targeting can selectively deliver anticancer drugs 
formulated as nanoparticles to the tumor tissue, exploiting the EPR 
effect. However, the drug needs then to be internalized from the tumor 
interstitium into the tumor cell to exhibit its biological activity. 
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Active targeting 
 
Active targeting of nanoparticles is obtained by attaching a component 
to the nanocarrier structure that recognizes a target within the tumor-
affected organ, tissue, cell or intracellular organelle, that results in a 
preferential accumulation of nanoparticles. Long circulating times will 
allow for effective transport of nanoparticles to the tumor site through 
the EPR effect and the targeting molecule can increase endocytosis. 
Since the surface of the nanoparticle interacts with the target, the ligand 
should be in sufficient quantity to allow multipoint binding at the tumor 
site.  
In addition, after administration the ligand should be not easily 
degradated nor have any immunogenic effect. The ligand should also be 
easily internalized into the tumor cell and then the drug should be easily 
released. 
After he releasing of the drug, the ligand should be readily hydrolized 
and cleared from the body without causing any toxicity. 
 
Here two examples of active targeting systems: 
 
 Ligand-Receptor Targeting 
This kind of targeting is usually achieved by incorporating a 
molecule that binds a receptor, uniquely expressed or 
overexpressed on the tumor cell surface, in a specific manner. 
This targeting mechanism via receptor-mediated endocytosis 
has been shown to result in an efficient drug uptake in many 
human cancers[10][11]. 
 Antibody-Antigen Targeting 
This strategy consists in using a monoclonal antibody (mAb) to 
selectively deliver a drug to a tumor cell. In particular, mAbs 
bind to antigens selectively expressed on the surface of the 
tumor cell. After this, the mAb gets absorbed into the cell via 
receptor-mediated endocytosis, thus taking the drug into the 
targeted cell.It is of fundamental importance the presence of a 
trigger moiety in order to initiate the cleavage of the drug[12]. 
21 
 
It is important to underline that the active targeting process cannot be 
separated from the passive one, because it occurs only after passive 
accumulation in tumors. 
 
 
Figure 1: Active and passive targeting 
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Nanoparticle uptake by tissues[5][
 
A succession of several membrane layers provide an obstacle for 
therapeutic agents attempting to target the intracellular environment.
During this process compound is lost due to ineffective partition across 
biological membranes. 
The extent of partition across a membrane is 
polarity of a molecule: non polar or lipophilic molecules easily bypass 
this obstacle , generally by diffusion. 
One interesting feature of nanoparticles is that they are able to mask a 
therapeutic agent  from its biological environment, thus limiting the 
influence of a compound's physical properties on intracellular drug 
concentration. 
Nanoparticles are ingested by cells through a mechanism called 
endocytosis, that includes three subtypes
 
Figure 2: 
 
 Phagocytosis: it involves the ingestion of materials with a 
diameter up to 10 µm and can be accomplished by few cell types 
of the RES system, such as macrophages, neutrophils and 
dendritic cells. 
 Pinocytosis: ingestion of sub
accomplished by virtually all types of cells.
13] 
 
directly related to the 
 
 (Figure 2): 
 
Endocytosis 
-micron material. It can be 
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 Receptor-mediated endocytosis: the cellular membrane is dotted 
with many receptors which, upon extracellular binding to their 
respective ligands, transduce a signal to the intracellular space. 
This signal can initiate a variety of cellular events, like for 
example the internalization of the ligand and its appended 
nanoparticle by endocytosis. 
The most typical receptor- mediated endocytosis pathways are 
the clathrin- and caveolae-mediated one[14]. 
 
 
Receptor-dependent clathrin-mediated endocytosis (CME) 
 
Clathrin is a three-leg structure called triskelio. More triskelia assemble 
in a polyhedral lattice just on the cytosolic surface of the cell membrane, 
which deform the membrane into a coated pit of ∼150 nm. 
As the clathrin lattice formation continues, the pit becomes deeper and 
deeper until the final fission of the vesicle mediated by GTPase dynamin, 
forming the clathrin-coated vesicle. Later uncoating of the vesicle allows 
the recycling of clathrin units. 
This vesicle deliver its cargo to "early endosomes", that then mature into 
"late endosomes" which generate a harsh environment that cause the 
degradation of the internalized material (Figure 3B). 
 
Caveolae-mediated endocytosis 
 
Although CME is the predominant endocytosis mechanism, alternative 
pathways have been recently identified, and among them the claveolae-
mediated one is the most relevant. 
Caveolae are flask-shaped membrane cavities  having a size typically in 
the range of 50-80 nm. They are lined by caveolin and enriched with 
cholesterol and sphingolipids.  
After binding to the cell surface, particles move along the plasma 
membrane to caveolae cavities, that then undergo the membrane fission 
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thus generating caveolae vesicles, that follow a cellular pathway similar 
to that of clathrin-coated ones (Figure 3C). 
 
 
Figure 3: Clathrin- and Caveolae-mediated endocytosis pathways 
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Nanoparticle clearance from the body and long-circulating 
nanoparticles (Stealth®) 
 
Upon intravenous injection to mice and rats, nanoparticles are rapidly 
cleared from the blood stream by the reticuloendothelial system (RES). 
In particular Kupffer cells are the major liver site for cell accumulation 
of nanoparticles: these phagocytic cells cannot directly identify 
nanoparticles themselves, but rather recognize specific opsonin 
proteins bound to the surface of the particle. 
The process by which a foreign organism or particle is covered by 
opsonin proteins, thus becoming more visible to phagocytic cells is 
called opsonization. Opsonins are thought to come into contact with 
particles typically by random Brownian motion. Once sufficiently close 
to the particle, several attractive forces(including van der Waals, 
electrostatic and others) lead to the binding of opsonins to the surface. 
After opsonization, phagocytosis can occur, which is the engulfing and 
eventual destruction or removal of foreign materials from the blood 
stream. If particles are not biodegradable, they can accumulate, leading 
to toxicity and other side effects. 
The third and last step in the clearance process is the ingestion of 
foreign materials by phagocytes. This step typically involves the 
endocytosis of the particle and then the secretion, by phagocytes, of 
enzymes and factors that destroy the particle. 
Most non-biodegradable particles cannot be degradated by this process 
and, depending on their size and weight, they will be removed by the 
renal system or sequestered and stored in one of the RES organs. 
Since the initial opsonization step is so critical for the clearance process, 
most research in the area of stealth drug delivery has been focused on 
trying to stop or block this step. 
As general rule, the opsonization of hydrophobic particles, as compared 
to hydrophilic particles, has been shown to occur more quickly due to 
enhanced adsorbability of blood serum proteins on these surfaces[15]. 
Therefore, one widely used method to slow opsonization is the use of 
surface adsorbed or grafted shielding groups which can block the 
electrostatic and hydrophobic interactions that help opsonins binding.  
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Generally, these groups are long hydrophilic polymer chains and non-
ionic surfactants, such as polysaccharides, polyacrylamide, PEG and 
PEG-containing copolymers[16][17][18].  
 
Recently[19] Pignatello and coworkers described stealth solid lipid 
nanoparticles (SLNs) formed by amphiphilic conjugates of m PEG2000 
and mPEG5000 carboxylic acids with a lipoamino acid as lipid anchor 
(mPEG-C-LAA18, Figure 4): 
 
 
Figure 4: mPEG2000C-LAA18 (m=44) and mPEG5000C-LAA18 (m=96) 
 
These conjugates produced uniformly dispersed SLN systems, with a 
mean diameter in the range of 250-270 nm. Incubation with 
macrophages of SLNs at different concentrations of mPEG-C-LAA18 
shown that increasing the PEG derivative concentration also the ability 
to reduce the cell uptake was increased. At 3% molar concentration of 
PEG, until the second hour of incubation all nanoparticles were able to 
circunvent the cellular uptake (Figure 5a) while, after 4 h, the systems 
started to be recognized and phagocytized (Figure 5b). 
 
 
Figure 5: Fluorescent microscopy pictures of J-774 macrophages culture 
incubated with mPEG5000C-LAA18 after 2 h (Panel A) and 4h (Panel B) 
 
Yeo and coworkers described[20] 
chitosan (LMWC) as an alternative stealth coating, responsive to the pH 
of tumor cells. 
Chitosan is a linear copolymer of glucosamine and 
obtained by partial (>50%) N-deacetylation of chitin, the second most 
abundant natural polymer. The primary amines provide chitosan with a 
unique pKa of 6.5, which matches the weakly acidic pH of tumor tissues.
In the acidity of the extracellular matrix of solid tumors, chitosan is 
protonated and can adhere to cells via electrostatic interactions with 
glycocalyx on the cell membrane. 
LMWCs with various molecular weights (MW
conjugated to poly(lactic-co-glycolic acid) (PLGA). The derivatives were 
formulated as nanoparticles and then loaded 
 
When incubated with J774A.1 macrophages,
effectively avoided the uptake, whereas PLGA
by them.  
Figure 7 J774A.1 macrophages incubated with PLGA
3 h at pH 7.4. Overlaid images of NP (green), nuclei (blue), and transmission images
Figure 6: PLGA-LMWC nanoparticles
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the use of low molecular-weight 
N-acetylglucosamine, 
 
s) were covalently 
with paclitaxel (PTX). 
  PLGA-LMWC2−4k NP 
* NP was readily taken up 
 
* NPs or PLGA*-LMWC2−4k NPs for 
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Furthermore, PLGA-LMWC4−6.5k mP showed greater reduction in protein 
adsorption than PLGALMWC2−4k. The difference may be explained by the 
greater coverage of the  surface by LMWC4−6.5k, given the LMWC 
content. 
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Squalene  
 
Chemical structure and phisico-chemical properties  
 
Squalene is an acyclic triterpene of formula C30H50 so named because of 
its occurrance in shark liver oil. However it is widely distributed in 
nature, with very significant amounts in olive oil and olive leaves. 
Squalene contains two farnesol moieties joined in a tail-to-tail fashion 
by the enzyme squalene synthase, obtaining a structure in which 6 
double bonds, 10 methylenes and 8 methyl groups are simmetrically 
distributed respect to the C12-C13 bond (Scheme 1): 
 
 
Scheme 1: Squalene biosynthesis 
 
Even if squalene is a free-flowing oil at room temperature, crystals have 
been obtained at low temperature and subjected to X-ray diffraction 
analysis[21]. 
The molecular structure displayed a symmetrical and stretched 
conformation: this result contrasted with the highly coiled conformation 
proposed to explain the terminal selectivity observed in the course of 
the oxidation of squalene by NBS in THF containing water[22]. Based on 
NMR and molecular calculation studies[23][24] it has been proposed that 
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in a solvent of low polarity squalene would exist for the most part in an 
uncoiled fully extended state, with all of the double bonds equally 
vulnerable to attack by an oxidizing agent.  
On the other hand, in a more polar medium squalene would assume a 
more highly coiled, compact conformation: in this case, the internal 
double bonds in the coiled conformation might be sterically shielded 
and thus chemically less reactive, whereas the terminal olefinic links 
remain exposed (Figure 8). 
 
 
 
Figure 8: Compact conformation of squalene in highly polar solvents 
 
This kind of folding maximizes the intramolecular lipophilic interactions 
and minimizes the contacts with the solvent, which is less lipophilic than 
squalene itself (oil drop effect)[23]. 
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Squalene emulsion-based adjuvants for vaccine delivery  
 
Squalene is frequently used in the preparation of stable emulsions as 
either the main ingredient or secondary oil[25][26].  
The high stability of squalene containing emulsions to its highly 
hydrophobic character: in fact, being almost insoluble in water, the 
diffusion from a small oil droplet to a larger one through the aqueous 
medium (Ostwald ripening, Figure 9) is very unlikely. For this reason 
squalene can be used in combination with other oils to reduce their 
tendency for Ostwald ripening and increase emulsion stability. 
 
 
Figure 9: Schematic representation of Ostwald ripening 
 
Squalene emulsions have been used for various applications, especially 
as immunological adjuvant in the delivery of vaccines, that is as 
substance employed to increase or to modulate the potency of the 
immune response while remaining non-toxic and safe for the host[27].  
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Squalene as a potential protective and preventive agent in cancer 
treatment  
 
Although squalene by itself is a weak inhibitor, it has been shown to 
prevent or arrest tumor growth in conjunction with anticancer drugs in 
various experimental tumor models[28]. Many studies demonstrated that 
squalene is a potential chemopreventive agent, especially for breast, 
pancreatic, colon carcinomas, and similar tumors associated with ras 
oncogene mutations[29].  
In general, squalene likely protects against carcinogenesis by the 
following mechanisms:  
 
 inhibition of Ras oncoprotein farnesylation as well as restricting 
the conversion of HMG CoA to mevalonate, which is necessary 
for DNA synthesis and cell proliferation, by indirectly inhibiting 
HMG CoA reductase via negative feedback regulation of 
endogenous cholesterol synthesis;  
 modulating biosynthesis and function of xenobiotic metabolizing 
enzymes, thus altering the metabolic activation of carcinogens;  
 acting as a free radical scavenger[28].  
 
Squalene as an emulsion has been reported to contribute either directly 
or indirectly to the treatment of cancer through a potentiation effect on 
co-administered anticancer agents[30][31].  
Moreover squalene has been shown to display selective cytoprotective 
activity, protecting normal but not tumor cells from chemotherapeutic 
toxicity: for instance, squalene protected normal bone marrow colony 
forming units, but not neuroblastoma tumor cells, from cisplatin and 
other anticancer drug-induced toxicity[32]. 
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Squalene’s protective effects against other diseases  
 
Shark liver oil, a source of squalene and alkylglycerol, is reputed to 
provide protection against bacterial and fungal infections, especially 
when administered to patients suffering from atopic dermatitis caused 
by xerosis and skin lesions[33]. Squalene alone is also believed to protect 
the skin from ultraviolet radiation-induced damage because a high 
percentage of squalene (about 12%) is secreted in sebum[34]. This 
natural triterpene accumulates in high concentrations in the skin, where 
it plays a vital role in quenching free radical oxygen (oxygen singlets), 
thus preventing harmful effects of lipid peroxidation.  
Furthermore, squalene and phenolic compounds in olive oil have been 
shown to provide considerable protection against coronary heart 
disease and aging[35].  
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Squalene as a drug carrier  
 
Drug carriers offer various advantages to passenger therapeutics: they 
allow administration of poorly soluble compounds, protect drugs from 
undesirable plasmatic metabolism, improve half-life, modify 
biodistribution, reduce toxicity, and facilitate drug targeting[36][37].  
Lipids have gained significant attention for the purposes of drug 
delivery for a wide variety of reasons including biocompatibility, 
inertness, nontoxicity, and ability to fuse with cell membranes or to 
transport biologically active compounds through them.  
Squalene has so far been used as a drug carrier in either emulsions or 
squalene-drug conjugates. For instance, a squalene emulsion stabilized 
by phosphatidylethanolamine or poloxamer 188 was shown to prolong 
in vitro release of a morphine prodrug[38].  
Administered intravenously in vivo, these prodrug-loaded squalene 
emulsion formulations exhibited prolonged analgesic activity in rats. 
Similar emulsions have been successfully employed to deliver lipophilic 
ester prodrugs of nalbuphine (a κ-opioid receptor agonist with a short 
halflife)[39].  
The concept of lipid-drug conjugates has gained considerable attention 
in recent years[40][41]. Various lipid-drug conjugates have now reached 
Phase I/II clinical trials, such as a docosahexaenoic acid conjugate of 
paclitaxel (Taxoprexin, Protarga Inc., USA)[42], an elaidic acid conjugate 
of cytarabine (Elacyt, Clavis Pharma, Norway)[43], and a cardiolipin 
conjugate of gemcitabine (Neopharm Inc, USA)[44]. The lipid-drug 
conjugates are usually obtained by covalent coupling of the drug to 
biocompatible lipid moieties. In some cases, these bioconjugates have 
been shown to improve pharmacokinetics, decrease toxicity, and 
increase the therapeutic index of the associated drugs. 
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Squalene nanoparticles  
 
In this context, it has been disclosed by Couvreur and coworkers[45] that 
the covalent linkage of squalene to hydrophilic drug molecules led to the 
formation of amphiphilic bioconjugates that self-assembled in water 
without the need of any surfactant. 
Squalenoylation is an original technology platform for generating more 
potent anticancer nanometer-scale medicines. This concept is to 
chemically link a terpenoid to a biologically active drug molecule in 
order to create a bioconjugate, which can self-aggregate as 
nanoassemblies in water without the need of any other transporter 
material and without any surface active-agent, which, from a 
toxicological point of view, would be a major advantage for intravenous 
administration[46].  
This concept was firstly demonstrated with the nucleoside anticancer 
agent gemcitabine (2,2'-difluorodeoxycytidine).  
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Squalenoylation of gemcitabine 
 
Gemcitabine (2′,2′-difluorodeoxyribofuranosylcytosine) is an anticancer 
nucleoside analogue active against a wide variety of solid tumors, 
including colon, lung, pancreatic, breast, bladder and ovarian cancers. 
However, following intravenous administration, this drug is rapidly 
inactivated by enzymatic deamination and displays a short biological 
half-life, thus necessitating the administration of high doses that lead to 
unwanted side effects[47].  
The gemcitabine squalene bioconjugate (SqGem, Figure 10) overcomes 
the above drawbacks by self-aggregating in water as nanoassemblies 
(with a diameter in the range of 100-300 nm)[45].  
 
 
Figure 10: a) Gemcitabine (Gem); b) 1,1',2-trisnorsqualenic acid; c) 4-(N)-
trisnorsqualenoyl gemcitabine (Gem-Sq) 
 
The ability of squalene to form nanoassemblies when linked with 
gemcitabine was explained both by the amphiphilic character of the 
bioconjugate, the squalene corresponding to the lipophilic moiety, 
whereas the gemcitabine represented the hydrophilic part of the 
molecule, and, of course, by the capability of squalene itself to form 
spontaneously nanoassemblies in polar medium. 
The anticancer activity of Gem-Sq nanoparticles was evaluated in vitro 
on the MCF-7 and KB3-1 cancer cell lines and showed that Gem-Sq 
aggregates wereabout 6- to 8-fold more cytotoxic than gembcitabine 
itself. When Gem-Sq NP were separated from the cells by inserts with a 
pore size smaller than the particle diameter, the aggregates maintained 
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their cytotoxicity after 72 h incubation: that means that, even when 
physically separated from the cells they were able to deliver the active 
drug. This observation suggests that the aggregate form of Gem-Sq (i.e. 
nanoassemblies)is in equilibrium with Gem-Sq as individual molecules, 
the latter being responsible for the cytotoxicity observed. 
The anticancer efficacy of Gem-Sq NP was also determined after oral 
administration to F344 Fischer rats, finding that Gem-Sq NP were able 
to prolong the survival time of rats more than the free drug. 
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Squalenoylation of siRNA 
 
Small interfering RNAs (siRNAs) are one of the emerging therapies for 
the papillary thyroid carcinoma (PTC), usually associated with a somatic 
mutation of the RET proto-oncogene (RET/PTC1) that encodes for a 
membrane tyrosine kinase receptor not expressed in healthy cells.  
Recently, a siRNA specific for RET/PTC1 oncogene has been 
discovered[48], and this constitutes a very promising and specific 
therapeutic strategy, because RET/PTC1 is present only in tumor cells. 
However, in vivo delivery of siRNAs is a key challenge, due to the poor 
stability in biological systems and the low intracellular penetration 
because of their highly hydophilic and anionic character[49]. 
Couvreur and coworkers prepared[50] a siRNA-squalene derivative 
(siRNA-Sq, Figure 11) with the aim of protecting siRNA from 
degradation and of improving the cell delivery by increasing the overall 
lipophilicity.  
It is known that the modification of the 5'-hydroxyl groups of the siRNA 
strand can hamper the siRNA function, thus the authors linked squalene 
at the 3'-end of the 21-mer sense strand siRNA: 
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Figure 11: Couvreur's siRNA-squalene conjugate 
 
By a real time quantitative reverse transcription PCR (qRT-PCR) it was 
found that the RET/PTC1 oncogene was down-regulated and the 
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RET/PTC1 protein expression was decreased. Anyway, the cytotxicity 
evaluation of RET/PTC1 siRNA-Sq NPs in the same model (BHP 10-3 cell 
line) didn't show any cell growth inhibition. 
Noteworthy, a preliminary in vivo evaluation  showed that siRNA-Sq 
NPs were able to significantly reduce the tumor size, whereas the 
control siRNA didn't show any statistical difference respect to the 
control saline. 
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Squalenoylation of penicillin 
 
Beta-lactams are one of the most important class of antibiotics. They can 
be used to treat infections caused by a variety of pathogens, but they 
suffer from a low intracellular uptake due to their weakly acidic 
character. One of the strategies to overcome this problem was the use of 
nanoparticulate carriers[51], such as antibiotic-loaded liposomes[52] and 
polyalkylcyanoacrilate nanoparticles[53]. However, the drug loading was 
poor, thus necessitating the administration of a high amount of 
nanoparticles that in some cases resulted in side effects. 
In order to overcome this limitations, Couvreur and coworkers prepared 
two amphiphilic squalene derivatives of penicillin G (PNG) containing a 
pH-sensitive or pH-insensitive bond[54] (Figure 12): 
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Figure 12: Penicillin G (PNG) and Couvreurs's squalene-PNG conjugates 
These bioconjugates were able to spontaneously self-assemble in water 
as NPs, yielding impressive antibiotic loading (44%); they also proved to 
induce fast and significant killing of S. aureus-infected J774 cells. 
Biological membranes are permeable only to the uncharged form of 
antibiotics, thus PNG, being negatively charged at physiological pH (in 
fact it's a weak acid), cannot diffuse inside infected cells. On the other 
hand, squalenoylated PNG-loaded nanoparticles enter into the cells 
through endocytic pathways and accumulate in acidic late endosomes, 
where their pH-sensitivity triggers the release of free PNG. 
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Squalenoylation of paclitaxel 
 
In 2010 Dosio[55] and coworkers described the preparation of a small 
collection of conjugates (Figure 13) in which a paclitaxel (PTX) molecule 
was covalently linked to a squalene tail using different linkers: 
Ph NH
O
Ph O
O
O
OAcO
HO
OH
O
OBz
H OAcO
Sq
Sq =
Ph NH
O
Ph O
O
O
OAcO
HO
OH
O
OBz
H OAc
Ph NH
O
Ph O
O
O
OAcO
HO
OH
O
OBz
H OAc
Ph NH
O
Ph O
O
OH
OAcO
HO
OH
O
OBz
H OAc
O O
N
H
Sq
O
O
O
O Sq
Ph NH
O
Ph O
O
O
OAcO
HO
OH
O
OBz
H OAcO O
N
H
O NH
Sq O
3
Ph NH
O
Ph O
O
O
OAcO
HO
OH
O
OBz
H OAcO O
N
H
O
N
H
Sq
11
O
PTX-Sq
a
b c
d
Paclitaxel (PTX)
 
Figure 13: Dosio's collection of paclitaxel-squalene conjugates 
All these compounds were able to self-assemble in water, leading to 
stable nanoparticle suspensions, with a PTX loading in the range of 45-
69%.  
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This was a priori unexpected with regard to the dramatic lipophilicity 
and absence of amphiphilicity of the conjugates. 
In vitro cytotoxicity was evaluated in M109 murine lung carcinoma cell 
lines, and the results are summarized in Table 1: 
 
Compound IC50 (nm) 
PTX 9.0±2.65 
PTX-Sq 175.0±5.51 
a 365.0±5.3 
b 490.0±4.58 
c 6450.0±7.0 
d 16500.0±7.81 
Table 1: IC50 (nm) of Dosio's PTX-squalene conjugates 
 
Even if these compounds showed to possess a cytotoxic activity, they 
still remain less active than their parent drug, and also unsatisfactory 
results were obtained from the in vivo evaluation. This decrease in the 
activity could be due to an incomplete release of the drug, because of the 
covalent bond between the two moieties. In fact, it is well known that 
the hydroxyl group at the 2'- position has a significant relevance for the 
biological activity of paclitaxel. 
Castelli and coworkers investigated also the possibility to incorporate 
compound a into dimyristoylphosphatidylcholine (DMPC) multilamellar 
vesicles (MLV)[56]. MLV were prepared empty and loaded with a and 
paclitaxel as a comparison and analyzed by differential scanning 
calorimetry experiments, that can reveal the effect caused by insertion 
of "stranger" molecules inside the vesicles by the variations in 
thermotropic parameters, such as transition temperature (Tm) and 
enthalpy change (ΔH), usually dependent on the amount of compound 
interacting with MLV. 
PTX-Sq resulted much more able to interact with MLV than paclitaxel 
and remained inside them. This is probably due to its increased 
lipophilicity and, thus, affinity for phospholipid bilayers. 
43 
Improvement of the squalenoylation platform 
 
On the base of the results obtained for compound PTX-Sq, Couvreur and 
coworkers prepared a small collection of its analogues, in which 
paclitaxel and squalene units were connected together by six different 
1,4-cis,cis-pentadiene units[57] (Figure 14). 
This idea came from another analogue of paclitaxel: docosahexaenoic-
acid-paclitaxel (DHA-PTX, Taxoprexin). This is a very promising slow-
release conjugate that reached the phase III clinical trial for the 
treatment of metastatic malignant melanoma and, even if DHA and 
squalene moieties are very similar, DHA-PTX is much more active than 
PTX-SQ. 
Since the major difference between these two lipophilic moieties 
seemed to be the absence of methylene groups, the authors decided to 
intercalate a spacer between PTX and squalene tail, not to disrupt the 
self-organizing properties of the resulting conjugates. 
 
 
Figure 14: Analogues of compound PTX-Sq 
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In vitro biological evaluation showed that these compounds displayed 
notable cytotoxicity on several tumor cell lines, compounds 1f anf 1g 
being the most promising ones. 
For f and g also in vivo activity was evaluated but unfortunately, while 
being better tolerated (MTD for PTX-Cremofor EL: 10 mg/kg, MTD for f, 
g: 32 mg/kg), they resulted less active than PTX-Cremophor EL. 
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Self-immolative linkers 
 
The squalenoylation platform enlights how the covalent linkage 
between a squalene molecule and a drug unit can modulate the physical 
properties of the latter, improving its cellular uptake. It can happen that 
the derivative thus obtained shows a good biological activity, but in 
most of the cases it results lowered because a functional group 
necessary for the activity of the drug unit is involved in the linkage. 
In these cases a good strategy could be to connect the two portions in a 
cleavable way (Figure 15a) or by attaching a triggering moiety that, 
upon specific conditions or in the presence of specific enzymes, is able 
to start a cascade that ends with release of the drug (Figure 15b). In the 
latter case, the linker forms a scissible bond with a protecting group and 
a stable bond with the drug unit, that becomes labile upon removal of 
the protecting group, resulting in a rapid disassembly of the three 
components (self-immolative elimination)[58]. 
 
 
 
Figure 15: Different approaches for drug release 
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Some examples of self-immolative linkers including their mechanism of 
drug release are summarized in Table 2[59]: 
Linker Reaction type Release mechanism 
 
1,6-benzyl 
elimination 
 
 
1,4-benzyl 
elimination 
 
 
1,8-elimination 
 
 
β-elimination 
 
 
Cyclization 
(lactonization) 
 
 
Cyclization 
(lactonization) 
 
 
Cyclization 
 
 
Table 2: Self-immolative linkers and their mechanism of drug release; = Protecting 
group; = Drug unit; X, Z = O, NH   
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The evolution of self-immolative linker technology has led to self-
immolative systems capable of amplified release, such as dendrimers 
(Figure 16a) and polymers (Figure 16b). 
 
 
 
Figure 16: Dendrimer and polymer disassembly 
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Summary 
 
On the base of these examples we can conclude that squalenoylation of 
active molecules results in the possibility to overcome some of the 
problems connected to a low water solubility of hydrophobic drugs, 
such as paclitaxel.  
Furthermore, squalene derivatives are more lipophilic than "free" 
compounds, and so the attachment of a squalene tail to hydrophilic 
molecules, such as gemcitabine, can improve the penetration through 
phospholipidic membranes. 
Anyway, it can happen that, in order to show a higher activity, the 
parent drug needs to be released from the squalene conjugate. This can 
be accomplished by the action of specific enzymes or by the presence of 
labile mioeties that are cleaved in specific conditions (pH, temperature 
etc[7]). 
For these reasons the preparation of drug-releasing squalene 
derivatives could be a good strategy for improving the delivery of drugs. 
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Section 2: Disulfide-containing  
Squalene conjugates 
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Disulfide-containing dimers of anticancer compounds 
 
In the last years our research group investigated the possibility to 
improve the biological activity of anticancer compounds by modifying 
their structures in order to overcome some drawbacks associated to this 
molecule, such as low water solubility, low physiological stability etc. 
In particular we used different strategies: 
 
 Modifications based on modeling studies[60][61][62][63]; 
 Substitution of precise portions of the molecule with bioisosteric 
ones[64][65][66]; 
 Preparation of dimers, with possible applications to target-
guided synthesis[67][68][69][70][71]. 
 
Among them, the preparation of dimers (Figure 17) offers some 
advantages concerning the possibility to obtain a better stability, a 
higher quantity of compound that reaches the intracellular environment 
and to exploit all the aspects related to the nature of the linker used to 
connect the two drugs units. For example, it is possible to use linkers 
with polar substituents, in order o improve the water solubility or to 
introduce labile functional groups that can be cleaved in specific 
conditions related to the tumor environment. 
For these reasons we prepared different classes of homo- and 
heterodimeric compounds using different disulfide-containing linkers 
and different anticancer compounds (Figure 18 and Figure 18).  
 
 
Figure 17: General structure of homo- and heterodimeric derivatives  
of anticancer compounds 
 
 
52   
 
Figure 18: Drugs and linkers used for the preparation of our conjugates 
 
In fact, it is well established that in many kinds of tumor a high 
concentration of glutathione (GSH) is present inside cells (1mM instead 
of micromolar extracellular concentration) and that GSH is able to 
reduce disulfide bonds. 
So we hypothesized that, after reduction of the disulfide bond, our 
conjugates could be able to release the drugs, following , for example in 
the case of linker c, the closure of the thiolactone ring:  
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Scheme 2: Reduction of disulfide bond by GSH 
 
Interestingly, these conjugates were able to release the parent drugs 
after incubation with GSH. They showed also to possess a biological 
activity, even if lower than the corresponding free drugs. 
We also applied the so-called target-guided synthesis approach[71] to 
verify the ability of tubulin, when incubated with different S-S 
containing DTC-PODO dimeric compounds, to select by itself the 
building blocks that will lead to the more stabilized (and so more active) 
conjugate: ESI-FT-ICR-MS analyses revealed that the conjugate most 
stabilized by non-covalent interactions with the target was compound 
DTC-2 (Figure 19). 
 
 
Figure 19: Structure of compound DTC-2 
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Aim of the work 
 
On the base of our experience in the preparation of bivalent compounds 
in which two drug units are linked by a labile spacer able to release the 
active compound, we decided to go into the possibility of connecting two 
different compounds (a drug and a squalene tail) by a linker containing 
a disulfide bond (Figure 20). 
In this purpose, we started a collaboration with Professor F. Dosio 
(Università degli Studi di Torino, Dipartimento di Scienza e Tecnologia 
del Farmaco) in order to prepare a small collection of conjugates (Figure 
20) and to verify their ability to form nanoassemblies, thanks to the 
presence of squalene moiety, and to release the active drug inside the 
cells. In fact, this kind of compounds may undergo a disulfide exchange 
reaction in the intracellular environment thus releasing the active drug. 
 
Figure 20: General structure of our drug-squalene conjugates, structure of drugs we 
used and squalene 
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As active compounds we chose paclitaxel, podophyllotoxin, epothilone 
A, camptothecin and cyclopamine. In order to better elucidate the 
importance of the presence of the disulfide bond, we also prepared the 
corresponding derivatives in which the sulfur atoms were replaced by 
two methylene groups. 
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Our targets: tubulin-interacting compounds 
Paclitaxel 
 
Paclitaxel was first isolated in 1971 from the Western Yew Taxus 
Brevifolia by Wani, Wall and coworkers, who established its structure by 
X-ray crystallographic methods[72] (Figure 21). 
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Different from most anticancer drugs, PTX acts as a microtubule-
stabilizing drug, which inhibits cellular growth by preventing 
cytoskeletal microtubule depolymerization to free tubulin and 
disrupting the balance between polymerization and depolymerization, 
and thus leads to cessation of the cell cycle with arrest at the G2/M 
phase[73]. 
Despite its promising cytotoxic activity, many limitations in its clinical 
use are related to its low water solubility. For this reason paclitaxel is 
usually formulated in adjuvant Cremophor EL, that anyway has been 
reported to cause serious side effects, including hypersensitivity 
reactions, nephrotoxicity, cardiotoxicity and neurotoxicity [74]. 
Furthermore, significant side effects are also induced due to paclitaxel 
nonspecific, indiscriminate biodistribution in the body after 
administration.  
Therefore, many kinds of PTX analogues have been prepared[75], on the 
base of SAR studies, in order to improve water solubility while 
maintaining the activity, such as: 
Figure 21: Paclitaxel and Taxus Brevifolia 
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 7-PEG carbamates and carbonates: poly(ethylene glycol) (PEG) is 
known to enhance water solubility and reduce immunogenicity 
of high molecular weight protein adducts. Greenwald and 
coworkers reported[76][77] the synthesis of PEG-paclitaxel 
conjugated (Figure 22) in which the PEG portion and the drug 
unit were linked together via a carbamate or a carbonate 
functionality at the 7 position (not essential for the biological 
activity): 
 
Figure 22: 7-PEG carbamate and carbonate derivatives of PTX 
 
These compounds resulted approximately 30000 times more 
soluble than paclitaxel. 
 
 2'-derivatives containing base-labile moieties: Nicolaou and 
coworkers[78] prepared a small collection of paclitaxel analogues 
in which the 2'-hydroxyl group was functionalized with different 
groups having the following characteristics: ability to initiate 
their own cleavage thus generating paclitaxel in situ, ability to 
increase the water solubility and lability in basic conditions, as 
showed in Figure 23 (in fact some drug-resistant tumor cells 
have a basic microenvironment): 
 
 
Figure 23: Base-labile drug-releasing PTX derivatives 
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Both the two classes showed an improvement in the water 
solubility, the one of class two being higher. When tested against 
a broad range of cancer cell lines, these compounds showed an 
activity comparable to that of paclitaxel. Furthermore, paclitaxel 
was isolated from the acqueous medium of the cell cultures, 
proving the in vitro release of the active drug. 
 
 Reductively activated disulfide prodrugs: Vrudhula and 
coworkers prepared a series of unsymmetrical paclitaxel 
prodrugs[79] derived from 2,2-dimethyl-4-mercaptobutyric acid 
which contain polar moieties as part of the disulfide residue for 
increased hydrophilicity (Figure 24). 
 
 
Figure 24: Reductively activated PTX derivatives 
 
These compounds were able to be activated in the presence of 
dithiothreitol (DTT) and possess a good cytotoxic activity, even 
if slightly lower than paclitaxel. 
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Different approaches, obtained from SAR studies, for the preparation of 
paclitaxel analogues can be summarized as in Figure 25[80][81]: 
 
 
Figure 25: SAR studies for paclitaxel 
   
Another strategy is to find a different formulation to avoid the use of 
Cremophor EL, and also in this direction many efforts have been made 
and some good results have been obtained, such as those related to 
albumin-bound paclitaxel (Abraxane®)[82][83]84. 
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Figure 26: Epothilones and Sorangium Cellulosum 
Epothilone A 
 
The epothilones are a new class of natural cytotoxic compounds first 
isolated by Gerhard Höfle of the National Biotechnology Research 
Institute in Braunschweig, Germany from a cultured strain of the 
myxobacterium Sorangium cellulosum in the late 1980s [85][86]. The chief 
components of the fermentation process are epothilone A and B, with 
epothilone C and D found in smaller amounts. Trace amounts of other 
epothilones are also detected (Figure 26). 
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The structures of epothilones A and B include a 16-membered 
macrocyclic lactone that differs only in the presence of a hydrogen or 
methyl group, while epothilones C and D lack of the epoxide ring. 
Although the epothilones can already be made by fermentation, several 
research groups have reported methods for their total synthesis [87]. 
One example is the solid-phase synthesis of epothilone A proposed by 
Nicolaou and coworkers in 1997 (Scheme 3)[88]: 
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Scheme 3: First steps of Nicolaou's synthesis of epothilone A. Reaction conditions: a) 
1,4-butanediol, NaH, n-Bu4NI, DMF, 25°C, 12h; b) PPh3, I2, imidazole, CH2Cl2, 25°C, 3h; c) 
PPh3, 90°C, 12h; d) NaHMDS, THF/DMSO, 25°C, 12h; e) THF, 0°C, 3h; f) HF.py, THF, 25°C, 
12h; g) (COCl)2, DMSO, Et3N, from -78°C to 25 °C; h) LDA, THF, from -78°C to -40°C, 1h, 
then ZnCl2, THF, from -78°C to -40°C, 2h; i) DCC, DMAP, 25°C, 15h. 
 
In the last steps of the syntehsis a ring-closing metathesis leads to the 
formation of four different products that need to be separated by 
chromatography (Scheme 4): 
62   
 
 
Scheme 4: Final steps of epothilone A synthesis. Reaction conditions: j) CH2Cl2, 
 25°C, 48h; k) 20% TFA, CH2Cl2; l) 0°C, 2h. 
 
Epothilones, like paclitaxel, induce tubulins to form microtubules at low 
temperatures and without guanosine triphosphate or microtubule-
associated proteins [89]. 
Epothilones exhibit kinetics similar to those of paclitaxel in inducing 
tubulin polymerization into microtubules in vitro (filtration, light 
scattering, sedimentation, and electron microscopy) and in producing 
enhanced microtubule stability and bundling in cultured cells. 
Furthermore, these 16-membered macrolides are competitive inhibitors 
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of paclitaxel binding, exhibiting a 50% inhibitory concentration almost 
identical to that of paclitaxel in displacement competition assays. 
Epothilone A has been shown to be 2000 to 5000 times more active than 
paclitaxel in vitro against P-glycoprotein– expressing MDR tumors and 
cell lines as well as tumors resistant to the taxanes based on tubulin 
mutations. 
Unfortunately, epothilones showed to be unstable in mouse plasma, 
resulting in metabolites with a mass 18 units higher than the parent 
drugs, and it was subsequently demonstrated that administration of the 
esterase inhibitor bis(4-nitrophenyl)-phosphate produced an active 
result in the A2780 ovarian carcinoma tumor model.  
For these reasons many efforts have been made in order to synthetize 
epothilone analogues  with the goal of improving metabolic stability. 
 
Ixabepilone 
 
Ixabepilone is the lactam anlogue of epothilone B (Figure 27). It showed 
to be able to maintain the beneficial in vitro properties of the parent 
epothilones and, furthermore, in vivo studies proved ixabepilone to be 
stable to hydrolysis on incubation in both mouse and human sera. 
 
 
Figure 27: Epothilone B and Ixabepilone 
 
Pharmacokinetic analyses of this compound delivered as an i.v. bolus in 
mice showed rapid systemic clearance and extensive tissue distribution, 
with a terminal half-life of f3 h. The protein binding was 87% and 85% 
in mouse and human plasma,respectively, indicating the presence of 
substantial free drug in each species. 
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Ixabepilone possess a potent tubulin polymerization activity, similar to 
that of epothilone A or epothilone B and 2-fold lower than paclitaxel, 
and a highly potent cytotoxicity across a broad panel of tumor cells, with 
a median IC50 value of 2.9 nmol/L[90].  
Ixabepilone was mechanistically confirmed to block cells in the mitotic 
phase of the cell division cycle. Moreover, the concentration needed to 
arrest cells in mitosis corresponded well to the concentration required 
to kill cells over the same treatment duration. 
Importantly, a comparison of the cytotoxicity of ixabepilone and 
paclitaxel in cell lines with different mechanisms of drug resistance 
indicated that, like the natural product epothilones, the lactam retained 
sensitivity toward paclitaxel-resistant lines driven by drug efflux pumps 
as well as tubulin mutations.  
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Podophyllotoxin 
 
Podophyllotoxin[91] is a naturally occurring aryl tetralin lactone isolated 
from the genera Podophyllum. Due to its high toxicity, this compound is 
currently used only as local antiviral agent: in fact, it was found 
unsuitable for clinical use as an anticancer agent due to its toxic side 
effects. However, its semi-synthetic derivative etoposide is an important 
anticancer drug due to a mechanism of action based on the inhibition of 
the enzyme topoisomerase II. 
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Podophyllotoxin is able to inhibit the formation of the mitotic spindle: 
this microtubule disruption causes the cell cycle arrest at the G2/M 
phase and subsequently induces apoptosis[92]. 
In general, the binding behaviour of podophyllotoxin results in the 
partial unfolding of the secondary structure of β-tubulin at the carboxy 
terminus and prevents polymerization[93].  
Semi-synthetic podophyllotoxin derivatives, such as etoposide, are 
recognized as clinically useful drugs against various cancers, including 
small-cell lung cancer, testicular carcinoma, lymphoma and Kaposi’s 
sarcoma[94]. Even if these derivatives possess a superior 
pharmacological profile and broader therapeutic uses, the major 
drawback is the low water solubility that, for example in the case of 
etoposide, can cause severe allergic reactions. 
Figure 28: Podophyllotoxin, Etoposide and Podophyllum Peltatum 
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Tubulins and microtubules 
 
Tubulin is a heterodimeric protein composed of globular α and β tubulin 
subunits arranged in a polar head-to-tail fashion and represents the 
monomeric building block of microtubules, which are one of the 
fundamental structural components of cytoskeleton in all eukaryotic 
cells. 
Microtubules (MTs, Figure 29) are involved in such diverse cellular 
processes as cell division, locomotion and intracellular transport and 
they are dynamic polar structures. 
In vertebrate cells the centrosome acts as the major site of MT 
nucleation by lowering the critical concentration of tubulin required for 
polymerization and anchoring the minus ends of the resultant MTs. 
 
 
Figure 29: Tubulins and microtubules 
 
Fully assembled microtubules are long hollow cylinders ∼25 nm in 
diameter composed of laterally associated tubulin protofilaments. The 
number of protofilaments per microtubule can range from 10 to 18. 
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Microtubule-targeting drugs 
 
Drugs that target the MT can be classified into two main groups based 
on their mechanism of action (Figure 30): 
 MT-destabilizing agents (MDAs), such as podophyllotoxin and 
Vinca alkaloids, promote depolymerization and prevent 
polymerization of tubulin; 
 MT-stabilizing agents (MSAs), such as epothilones and taxanes,  
promote polymerization of tubulin and stabilize the polymer, 
preventing depolymerization. 
 
 
Figure 30: Microtubules stabilizing and destabilizing drugs 
 
The exact mechanism of mitotic arrest and consequent apoptosis 
induced by an MSA is still not fully understood. It is however widely 
accepted that their antimitotic action occurs through interference with 
the spindle dynamics within the cell. Affected cells fail to pass mitotic 
checkpoints and arrest at the 
G2/M phase of the cell cycle 
(Figure 31). G2/M block is the 
hallmark of MSAs. Cells blocked 
in G2/M subsequently undergo 
cell death MTs are also required 
for endothelial cell migration, and 
thus some MT-targeting agents 
are able to inhibit angiogenesis as 
well as mitosis, inhibiting 
vasculari-zation of tumors.  
Figure 31: Phases of the cell cycle 
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Interaction with microtubules 
 
Paclitaxel is a microtubule-
stabilizing agent that acts by binding 
to β-tubulin in assembled 
microtubules. The 2'-hydroxyl group 
is an absolute requirement for 
activity because it forms a persistent 
hydrogen bond with D26 within the 
binding site. Substituent at the 3'-
position function to orient the 2'-OH 
group for a productive hydrogen 
bond interaction with the 
protein[95][96](Figure 32). 
 
 
Epothilone A competitively inhibits 
the binding of paclitaxel to tubulin, 
suggesting that the two types of 
compounds share a common or 
overlapping binding site (Figure 
33).  
Anyway, even if Epo-A and PTX 
overlap in their occupation of a 
rather expansive common binding 
site on tubulin, each ligand exploits 
the binding pocket in a unique and 
qualitatively independent manner[97]. 
 
 
Podophyllotoxin From the crystal structure of the tubulin-
podophyllotoxin complex, it was observed that a threonine residue 
(Thr179) is present in close proximity with the 4¢-hydroxy group of ring 
D of podophyllotoxin (Figure 5). The measured distance (approximately 
3.4 Å) ensures a strong possibility of the interaction between the 
Figure 32: Binding mode of 
paclitaxel 
Figure 33: Binding mode of 
Epothilone A 
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carbonyl oxygen of Thr179 with 
the 4¢-hydroxy group of ring D 
on podophyllotoxin[98] (Figure 
34). 
Podophyllotoxin competes for 
the colchicine-binding site on 
tubulin. This podophyllotoxin-
mediated competitive inhibition 
of colchicine binding has been 
ascribed to the fact that both 
compounds possess a 
trimethoxy phenyl ring. 
  
Podophyllotoxin
α tubulin
β tubulin
Figure 34: Binding mode of 
podophyllotoxin 
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Our targets: Topoisomerase I inhibitors 
Camptothecin 
 
Camptothecin (CPT) is a pentacyclic alkaloid isolated in 1958 from 
Camptotheca Acuminata[99] (Figure 35) that acts as a selective inhibitor 
of the nuclear enzyme Topoisomerase I (TOP I). 
 
 
  
 
Figure 35: Camptothecina and Camptotheca Acuminata 
 
Unfortunately, therapeutic application of unmodified CPT is hindered by 
very low water solubility in aqueous medium, high toxicity and rapid 
inactivation through lacone hydrolysis in vivo. 
To overcome the solubility and stability issues, various derivatives have 
been developed. Although a number of small and large molecule 
compounds are currently in clinical trials, only two CPT derivatives, 
irinotecan and topotecan, are approved for clinical use (Figure 36)[100]. 
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Figure 36: Structures of camptothecin analogues 
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Irinotecan is currently used for metastatic colorectal cancer, while 
topotecan has been approved for ovarian cancer, cervical cancer and 
small-cell lung cancer.  
These derivatives employ tertiary amine cations to improve solubility 
and subsequently improve lactone stability.  
 
Substituted camptothecins 
 
To summarize the SAR studies, the A and B rings are the most tolerant 
to modification with substitutions at positions 7, 9, 10, and 11 
improving or retaining activity[101]. Interestingly, von Hoff has provided 
evidence that substitutions that increase hydrogen bonding at the 7-
position improve binding to TOP I, thus increasing activity over CPT[102].  
On the other hand, altering the C and D rings or substituting positions 
12 and 14 inactivates the molecules. 
Finally, the E-ring lactone is necessary for activity by binding to TOP I: 
Hydrolysis or removal of the lactone leads to loss of all activity. The 
equilibrium between the closed, active lactone and the open, inactive 
carboxylate form is influenced by both the affinity of the carboxylate for 
human serum albumin and the local pH in vivo (Figure 37).  
 
 
Figure 37: Lactone hydrolysis 
 
Since it's the site where binding to TOP I occurs, the E ring tolerates only 
minor modifications without dramatic, negative effects. For example, 
enlargement of the ring to form the betahydroxy lactone improves 
stability and drug activity. Interestingly, modification of the C20 
hydroxyl group through alkylation or acylation has been shown to 
stabilize the lactone[70]. Acylation is the favored method for linking CPT 
covalently to macromolecules. 
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In addition, different kinds of CPT formulations have been prepared in 
order to accomplish CPT delivery to tumor cells by passive targeting, 
including micelles[103], liposomes[104], chitosan nanoparticles[105] and 
hydrogels[106]. 
 
 
Interaction with Topoisomerase I 
 
CPTs gained much interest in the late 1980s when the molecular target 
was identified: DNA topoisomerase I (TOP I) is believed to be the single 
point of biological activity[107].  
Topoisomerase I acts clamping around DNA, nicking it, and forming a 
covalent bond between the active-site tyrosine and the 3' end of the 
DNA upstream of the cut, while 
hydroxylcapping the 5' end of the 
downstream DNA (Figure 38). After 
this enzymatic step, supercoils are 
relaxed by rotation of the DNA 
duplex downstream of the cut 
around the intact strand; the drive to 
rotate is provided by the energy 
stored in the supercoils and the 
number of full rotations of the 
downstream DNA equals the number 
of supercoils that are eliminated. 
Subsequently, the DNA backbone is 
religated, and the protein releases 
the DNA. 
 
The intermediate in TOP1-linked DNA breakage is referred to as a 
“cleavable complex”, because it is readily reversible to a noncovalent 
enzyme-DNA complex before or after topoisomerization of the DNA. 
Experimental studies[108] suggest interaction of CPT with both the 
enzyme and the DNA, forming a ternary complex that stabilizes the 
transesterification intermediate. 
Figure 38: TOP1-DNA "cleavable 
complex" 
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Modeling studies[109] suggest that the interaction of CPT with DNA and 
top1 involves pseudointercalation between the base pairs of DNA 
flanking the top1 cleavage site. The protein backbone of TOP I extends 
toward the major groove of DNA. The camptothecin molecule is oriented 
with the E ring near the DNA break, and the concave portion of the drug 
molecule faces the DNA major groove[110][111]. 
Upon binding to TOP I, CPT prevents religation and causes apoptosis 
(Figure 39). 
Interestingly, CPT exhibits little or no binding  to either DNA or TOP I 
alone. 
 
 
Figure 39: Binding of CPT to TOP1-DNA "cleavable complex" 
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Synthetic strategy 
 
As depicted in Figure 40, two disconnections have been individuated, in 
the correspondence to the ester bonds, obtainable via two condensation 
reactions from a compound containing two carboxylic groups and two 
different alcohols: 
 
 
Figure 40: General structure of our drug-squalene conjugates 
 
In order to minimixe the loss of active drug due to the not high yields of 
this kind of reactions, we decided to firstly effect the coupling between 
the spacer and the squalene portion and, in the end, to attach the drug 
unit. 
For this reason we started from the preparation of 1,1',2'-tris-nor-
squalene alcohol 5. 
The first step consists in the preparation of the terminal 
monobromohydrine of squalene (1), that means to differentiate the six 
non-conjugated double bonds, approximately equivalent. As already 
mentioned, this is possible because in very polar solvents squalene 
assumes a compact conformation in which just one of the terminal 
double bonds is available to react. 
The monobromohydrine 2 is then transformed in the corresponding 
epoxide 3 by treatment with K2CO3 in MeOH. After an oxidative opening 
of 3 with H5IO6 to give aldehyde 4 and consequent reduction with 
NaBH4, the final 1,1',2-tris-nor-squalene alcohol 5 is obtained, with an 
overall yield of 69% over four steps (Scheme 5). 
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Scheme 5: Synthesis of 1,1',2-tris-nor-squalene alcohol 5 
 
The final compounds have been prepared performing two consecutive 
condensations using EDC.HCl/DMAP as activating system in CH2Cl2 at 
room temperature for 3-96h (Scheme 6): 
 
 
Scheme 6: Synthesis of drug-squalene conjugates 8-11 
 
Using this pathway and starting from two different dicarboxylic acids 
6a, 6b (dithiodibutyric and sebacic acid) we were able to prepare a 
small collection of compounds (Figure 41): 
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Figure 41: Structures of drug-squalene conjugates 8-11 
 
Reaction times and yields for compounds 8-11 are summarized in Table 
3: 
Compound 
Reaction 
Time (h) 
Yield (%) 
8a 22 65 
8b 24 40 
9a 24 48 
9b 18 31 
10a 31 31 
10b 96 19 
11a 72 32 
11b 48 28 
Table 3: Reaction times and yields for the preparation of compounds 8-11 
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Nanoparticles formation and characterization 
 
Preparation 
 
In order to allow the formation of nanoassemblies, the solvent 
displacement method was applied.  
In a typical procedure, 4 mg of the conjugate were dissolved in 1 ml of 
EtOH, the solution was added dropwise to 2 ml of MilliQ water and then 
the organic solvent was removed under reduced pressure, with 
subsequent formation of a nanoaggregate suspension at a final 
concentration of 2 mg/ml (Figure 42). 
 
 
 
Figure 42: Typical preparation of a nanoparticle suspension 
 
All the compounds were able to self-assemble in water and the 
suspensions were characterized to determine the mean diameter, the 
polydispersity index and the Z-potential. 
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Characterization 
 
 Dimensional analysis: mean diameter and dimensional homogeneity 
(polydispersity index) of nanoassemblies were determined with 
quasi-elastic light scattering (QELS) experiments, at a fixed angle of 
90°, using a 90 Plus Particle Size Analyzer (Brookhaven Instrument, 
Co.). 
 Z-potential measurement: nanoassemblies surface charge was 
evaluated by measuring Z-potential, a parameter that controls 
electrostatic repulsion between adjacent particles, thus influencing 
the stability of the colloidal system. At low Z-potential values 
attractive forces prevail, while at high values repulsive forces prevail. 
In general it can be affirmed that colloidal systems are stable when 
their Z-potential assumes values between +30mV and -30mV. 
To determine the electrophoretic mobility, the NAs samples were 
diluted with 0.1 mM KCl and placed in the electrophoretic cell, where 
an electric field of 15.24 V/cm was established. Each sample was 
analyzed in triplicate. The zeta potential values were calculated using 
the Smolochowski equation. The results we obtained are summarized 
in  
Table 4: 
 
Compound 
Mean 
Diameter  
(nm) 
Polydispersity 
Index 
Z 
potential 
(mV) 
8a 103.2±0.7 0.052 -37.56 
8b 107.0±0.1 0.049 -20.78 
9a 184.3±2.4 0.063 -11.42 
9b 179.6±1.1 0.048 -28.47 
10a 161.6±6.8 0.090 -56.37 
10b 124.1±2.5 0.131 -25.39 
11a 195.2±6.8 0.083 -41.02 
11b 154.8±7.0 0.279 -39.14 
 
Table 4: Mean diameter, polydispersity index and Z potential  
of nanosuspensions of compounds 8-11 
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 Atomic Force Microscopy (AFM): to better elucidate the 
morphology of our suspensions we submitted a sample of 8a 
(considered as reference compound for our collection of 
conjugates) and a sample of PTX-Sq as a comparison to an 
Atomic Force Microscopy (AFM) analysis. Compound 8a forms 
nanoassemblies with a softer and less shaped structure, respect 
to PTX-Sq. This could mean that 8a nanosuspension is less stable 
that PTX-Sq one and, as a consequence, drug release inside the 
cell could be favoured.  
 
a)          b) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 43: AFM analyses of 8a (a) and PTX-SQ (b) 
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Stability assessment of drug-squalene conjugates and NAs  
 
Stability of the conjugates 
 
Dithiothreitol (DTT) 
 
To define the stability of disulfide bonds we used the method described 
by Satyam, with slight modifications[112]. Each drug-squalene conjugate 
was dissolved in acetonitrile or ethanol/acetonitrile mixture to obtain a 
1 mg/ml solution (0.5 ml) and then 10 µl of 0.2 M borate buffer (pH 9), 
50 µl of water and 20 µl of  a 16 mM solution of DTT in acetonitrile were 
added. The vials were capped and kept at room temperature under N2 
atmosphere, with occasional shaking by hand. For comparison the same 
solutions without DTT were prepared. Samples (20 µl) were spiked and 
analyzed by HPLC at various time points. For evaluating the release of 
drugs from the conjugates we monitored the disappearance of the major 
peak related to the pure compound (Figure 44).  
 
 
 
Figure 44:  HPLC analysis for compound 8a after 1h incubation with DTT 
 
Podophillotoxin derivative 9a was unstable and a rapid degradation due 
to basic environment appeared. 
The same analyses were carried on also for compounds 8-11b: both the 
buffer alone and DTT did not influenced the stability of the conjugates. 
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Glutathione (GSH):  
 
In order to verify the stability of conjugates 8-11a in the presence of 
GSH we applied the same procedure we used for other disulfide-
containing compounds[69][70]. 
Typical procedure: a solution of GSH (0.0058 mmol) in H2O (0.300 ml) 
was added to a solution of the drug-squalene conjugate (0.0058 mmol) 
in MeOH (3 ml) and the reaction mixture was stirred at room 
temperature for 24 hours. A sample of the reaction mixture was 
submitted to an ESI-MS spectrometry analysis in order to detect the 
presence of one or more of the possible products, and possibly the free 
drug (Figure 45).  
 
Figure 45: Possible products of the reaction of 8-11a with GSH 
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As showed by ESI-MS analyses, compounds 8-11a were able to release 
the parent drugs over a 24 hours incubation with GSH. 
The same analyses were carried on also for compounds 8-11b and, as 
expected, incubation with GSH didn't affect the stability of the 
conjugates. 
 
 
Stability of nanosuspensions 
 
Dithiothreitol (DTT):  
The same proportions of buffer and DTT (dissolved in water) used to 
prove the stability of our conjugates  were used to analyze also the 
stability of nanosuspensions. Samples at different times were diluted 
with acetonitrile (50 µl)  just before HPLC injection.  
All the NAs appeared stable when treated with DTT in borate buffer, 
with a very slow release of drug during the first two days. NAs size 
measurements during incubation did not present significant differences.  
 
Glutathione (GSH):  
 
Nanosuspensions (1 mg/ml)  were incubated with GSH (final 
concentration : 10 mM) at 37°C, sampling the size of NAs after different 
times (0, 1, 6, 24, 48, 78 h).  
For compounds 8a, 10a, 11a a progressive slight increase of size was 
evident but only for nanosuspension of compound 9a the size became 
dramatically increased and precipitation occurred.  
 
Serum: 
Furthermore nanosuspensions of compounds 8-11a were incubated in 
serum at 37°C for 48 hours, then samples were analyzed by HPLC.  
Compound 8a was the most stable while significant release occurred for 
9a and 11a derivatives (around 48-42% released).  
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Self-aggregation behavior of nanoassemblies 
 
The physical stability of the squalene-drug NAs was assessed in water. 
All the nanosuspensions were found to be remarkably stable at 5°C over 
a three-month period without any significant size modification. 
This unique ability of squalene-derivatives to form NAs in water was 
further confirmed by the critical aggregation concentration (CAC) 
measurement. 
The critical aggregation concentration test (CAC) was performed by 
steady state fluorescence spectra using a described procedure[55]. 
Briefly, samples of nanosuspensions in water, with concentrations 
ranging from 0.1 µg/L to 0.5 g/L were incubated  with a constant pyrene 
concentration of 0.6 µM for 12h at room temperature under stirring.  
Fluorescence emission spectra were recorded from 360 to 550 nm, 
using 343 nm excitation wave length. In the emission spectra of 
unstacked pyrene, the intensity ratio of the first band (I373) to the third 
band (I384) was analyzed as a function of NAs concentration. CAC values 
were determined from the intersection of the tangent to the curve at the 
inflection with the horizontal tangent through the points at low 
concentration. 
It has to be noted that the observed CAC values were higher than 
compound 16 but still lower than those of polymeric micelles used for 
drug delivery purposes (5-10 mg/L)[113].  
 
Compound 
CAC 
(mg/l) 
Mean 
diameter 
(nm) 
Mean diameter 
after 3 months 
(nm) 
8a  1.5 103.2 106.5 
8b  1.1 107.0 110.5 
9a  0.7 184.3 215.3 
9b  0.5 179.6 210.5 
10a 0.6 161.6 191.1 
10b  nd 124.1 142.9 
11a  nd 195.2 210.2 
11b  nd 154.8 172.4 
PTX-Sq  0.2 173.5 181.1 
 
Table 5: CAC values and mean diameters of nanosuspensions after  
three months since their preparation 
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Biological evaluation 
 
In vitro activity  
 
The cytotoxicity of squalene conjugates (NAs) was evaluated using MCF-
7 cell line (human breast cancer) by incubation for 48 h (Table 6). In 
order to check the release ability by reducing agent the same 
experiments were carried out after NAs treatment with DTT (10 mM). 
Comparison of the dose-response curves obtained for each drug and 
squalene conjugates NAs revealed that the conjugation to squalene 
decreased the cytotoxicity toward MCF-7 cell line for each compound 
(Table 6).  
Whereas MCF7 seems very sensitive to single drug (in nano and sub-
nanomolar range), the various squalene conjugates exhibited different 
IC50 values. There is not a direct correlation between cytotoxicity of free 
drug and conjugates, indeed the paclitaxel derivative 8a appeared 100 
times much toxic than the 9a, when the podophillotoxin is the most 
active free drug. In a scale of activity we can place 8a > 9a > 10a > 11a. 
The ability of a more efficient release of toxic moiety appeared evident 
comparing the disulfide linked and alkyl chain derivatives. These latter 
were active at very high concentrations ranging from 1 to 100 
micromolar. When incubated with DTT, NAs of compounds 8a, 9a, 11a 
allowed a better release of the active molecule as detected by a 10-fold 
increase of activity. In particular compound 8a reached an activity 
closer to free paclitaxel. As expected, treatment with DTT did not 
significantly changed the activity of  NAs made by compounds without 
the disulfide bond (8b, 9b, 11b) or native drugs.  
The cytotoxicity of our conjugates was also evaluated on A549 cell line, 
even if this case our compounds resulted less active (Table 6). 
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 MCF-7  
Compound 
IC50 
(µM) 
IC50 after 
treatment with 
DTT (µM) 
A549 
Paclitaxel 0.004 0.005 0.05 
8a 0.06  0.003 0.34 
8b 1.2 1.5 nd 
PTX-Sq 9 8.7 - 
Podophyllotoxin 0.0001 0.0004 0.06 
9a 0.4 0.06 7.6 
9b 105 110 6.2 
Epothilone A 0.0009 0.0008 >5 
10a 1 0.5 >5 
10b 40 45 >5 
Camptothecin 0.0005 0.0003 0.49 
11a 8 0.8 >5 
11b 10 20 >5 
Table 6: IC50 values (μM) of squalene conjugates and naïve compounds  
against MCF-7 and A549 cell lines  
 
 
Microtubule bundle formation (immunofluorescence)  
 
In order to confirm the anti-microtubule effect of squalene 
bioconjugates, we investigated microtubule structure and distribution 
in A549 cell line exposed 1h to 200 µg/ml of the conjugates or to equal 
concentration of parent compounds. Microscopy analyses revealed that 
control cells are spread with a well-organized microtubular network, 
whereas treated cells are shrinking, with no obvious differences 
following incubation with naïve compounds and squalene conjugates 
(Figure 46). As expected, paclitaxel and epothilone-A induced 
microtubule bundling; on the other hand, podophyllotoxin completely 
disrupts microtubules.  
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Figure 46: Microtubule network  (α-TUB staining, red) and nuclei (DAPI, blue) of A549 
cells not loaded (CONT) or incubated 1h with naïve compounds (naïve) or squalene 
conjugate (squalene) taxol (TAX) epothilone-A (EPO-A) and podophyllotoxin (PODO). 
Scale bar = 20 μm 
To verify that the observed effects were due to intracellular action of the 
squalene conjugates, at least for paclitaxel and its derivatives, we 
verified if they had retained the ability to cross the cell membrane.  
In this purpose, we removed unassembled tubulin, using previously 
described procedures[114] with minor modifications. With more detail, to 
avoid the administration of further taxol, we used a microtubule-
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optimized PEM buffer (85 mM PIPES, pH 6.94, 10 mM EGTA, 1 mM 
MgCl2, 2 M glycerol, 1 mM phenylmethylsulfonyl fluoride, 0.1 mM 
leupeptin, 1 μM pepstatin, 2 μg/ml aprotinin). After fixation and 
permeabilization, cells were double immunostained using a polyclonal 
anti-taxol antibody (abcam, Cambridge, UK) 1:1000 in PBS for 1 h at 
37°C and then a monoclonal anti-α-tubulin antibody. Afterward we used 
a mix of secondary antibodies, goat anti-mouse Alexa Fluor568 and 
donkey anti-rabbit Alexa Fluor488 (Life Technologies Italia, Monza, 
Italy). 
As showed in Figure 47, both naïve paclitaxel and its squalene conjugate 
enter into the A549 cells and stain microtubule bundles. 
 
 
Figure 47: Microtubule network (α-TUB, red), microtubule-binded 
taxol (TAX, green) and nuclei (DAPI, blue) of A549 cells not loaded  
(CONT) or incubated 1h with naïve paclitaxel (TAX) or squalene  
bioconugated taxanes (8a and PTX-SQ). Scale bar = 20 µm 
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In vivo activity  
 
The obtained results pointed out compound 8a as the most interesting 
obtained conjugate compound on the base of its stability, releasable 
capacity and cytotoxicity. We then planned to evaluate its behaviour in 
vivo.  
To this aim MDA-MB-231 tumor-bearing mice were randomized when 
their tumor masses were about 350 to 400 mg to receive 8a at the doses 
of 34 mg/Kg (23.6 mmol/Kg). Treatment was compared with the use of 
taxol (20 mg/Kg, 23.4 mmol/Kg). The results (Figure 48) show that 8a 
is not toxic (body weight is not affected by the treatment) and 
unfortunately it is not active in fact the tumor growth seems to be 
affected only after 40 days from the first treatment.     
 
 
 
Figure 48: Influence on tumor growth and body weight of the treatment (once each 7 
days for 21 days) with 8a (NAs) and comparison with  the treatment with paclitaxel. 
Doses at 20 mg /Kg (paclitaxel equivalent) 
 
The unpleasant result moved us to investigate the efficacy of paclitaxel 
release by 8a after the in vivo administration. We evaluated paclitaxel 
plasma and tumor levels. We selected 3 time points (1, 4 and 24 hours) 
after an intravenous dose of 20 mg/Kg paclitaxel (23.4 mmol/Kg) and 
compared with 34 mg/Kg (23.6 mmol/Kg) of 8a.  
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Figure 49 shows that after 4 h the level of paclitaxel in plasma is very 
low. This could be comparable with the situation of treatment with 
paclitaxel and could suggest a slow release of the drug, but the data 
regarding the level of paclitaxel in the tumor is whispering that release 
is not efficient in vivo. We investigated the level of paclitaxel in the liver 
and also in this case we detected a very low amount of drug.  
 
 
Figure 49: Paclitaxel plasma, tumor and liver levels in MDA-MB-231 tumor-bearing 
mice after treatment (once each 7 days for 21 days) with 8a (NAs) and paclitaxel. Doses 
at 20 mg /Kg (paclitaxel equivalent) 
 
Further studies in order to determine the amount of compound 8a in 
other organs are currently under investigation in the laboratories of Dr. 
Damia (Istituto Mario Negri, Milano).  
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Our targets: Cancer Stem Cells (CSCs) and their inhibitors 
Introduction 
The different organs in human organism are constituted by tissues with 
mature and specialized cells and its specific stem cells. Even if stem cells 
represent only a small fraction of cells that constitute each tissues, they 
are the only cells able to self-renew. The organ-specific stem cells have 
specific properties in order to maintain the tissue integrity and they 
have a fundamental importance due to their ability to undergo self-
renewal and differentiation into a variety of mature cells. 
Malignant neoplasias are believed to result from sequential mutations 
that can occur as a consequence of progressive genetic instability 
and/or environmental factors.  
The cancer stem cells (CSCs) hypothesis postulates that normal stem 
cells may be the origin of cancer, and that a specific subset of cancer 
cells with stem cells characteristics can give rise to a hierarchy of 
proliferative and differentiated bulk of tumor cells that result in tumor 
initiation, progression and recurrence. In fact specific CSC markers have 
recently been identified showing a similar expression also in normal 
stem cells of the same organ. Furthermore, when xenografted in 
immunodeficient mice, CSCs have been shown to possess the ability to 
give rise to new tumors.  
Additional confirmations that stem cells can play a role in 
carcinogenesis are the homologies between normal adult stem cells and 
cancer cells. Besides self-renewal capacity, these characteristics include 
the production of differentiated cells, activation of antiapoptotic 
pathways, induction of angiogenesis, resistance to apoptosis and drugs 
and the ability to migrate and propagate. Differently from normal adult 
stem cells, that remain constant in number, CSCs can increase as the 
tumor grow and originate a progeny that can be both locally invasive 
and/or colonize distant sites.  
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Stem Cells 
 
Despite the variety of cells in adult tissues, all cells derive from a single 
egg after fertilization of an ovule by a spermatozoid. Egg fertilization 
results in the creation of totipotent stem cells, precursors of all tissues 
of embryo. After approximately four days these totipotent stem cells 
undergo several mitotic divisions to form identical cells and, after this 
point, they tend to gradually lose their high proliferative potential and 
begin to specialize, until they become nullipotent (Figure 50). 
 
Figure 50: Stem cells plasticity 
In most adult tissues there are pools of progenitor cells that are able to 
multiply and differentiate into specialized tissues of origin and, at the 
same time, to maintain a reserve of undifferentiated cells. These adult 
progenitor cells are defined somatic stem cells. 
Due to its remarkable regeneration capacity, the liver is probably the 
best example of a tissue with stem cells and differentiated cells. 
 
Stem cells can divide in two different ways (Figure 51):  
 symmetrically: two daughter cells share the same stem cell 
feature. It occurs when their number (stem cell pool) needs to be 
expanded, such as during embryonic development and after 
tissue injury. 
 asymmetrically: one of the progeny remain undifferentiated, 
replenishing the pool of stem cells, while the other daughter cell 
can proliferate and differentiate into specialized cells to 
generate new tissue mass. 
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Figure 51: Stem cells  symmetrical and asymmetrical division 
 
In summary, stem cells differ from other cells in the body because they 
have four major properties: 
 they are undifferentiated and unspecialized; 
 they are able to multiply for long periods while remaining 
undifferentiated; 
 they are capable of differentiating into specialized cells of a 
particular tissue; 
 they can be serially transplanted. 
 
The combination of these properties is called "stemness". 
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Stem cells and cancer 
Normal adult multipotent stem cells are usually able to self-renew, 
producing at least one progeny cell with a similar developmental 
capacity and many evidences indicate that this cell population, through 
initial genetic or epigenetic alterations, can become responsible for the 
development of several tumors through a progressive establishment of a 
CSC population. 
The CSCs model suggests that tumor progression, metastasis and 
recurrence after therapy can be driven by a rare subset of tumor cells 
that have the capacity to self-renew, while the bulk of the tumor doesn't 
have this capacity. 
For these reasons the deregulation of the self-renewal process may be a 
key event in carcinogenesis, and while self-renewal can drive 
tumorigenesis, the differentiation process may contribute to tumor 
phenotypic heterogeneity. 
 
CSCs as targets for cancer treatment 
It is well known that several cancers are peculiarly resistant to 
conventional radio- and chemotherapy that typically kill the majority of 
cancer cells. This clinical response may reflect the targeting of the bulk 
of non-stem cell population. 
On the other hand, there are several specific key intracellular signaling 
pathways implicated in CSCs self-renewal and proliferation processes 
that appear to be promising therapeutic targets. 
An ideal therapeutic strategy might be to sensitize CSCs to chemo- and 
radiotherapy by inhibiting their stem properties and then by promoting 
a direct cytotoxicity. Since the CSCs population is driven by embryonic 
signaling pathways, the targeting of these pathways could result in a 
better outcome of the therapy: in this direction, many drugs for the 
inhibition of embryonic signaling pathways are currently under 
development. 
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Hedgehog Signaling Pathway: a new biological target for the design 
of new anticancer compounds 
 
Some of the most characterized signaling pathways controlling self-
renewal and differentiation in adult stem cells, such as Wnt/b-catenin, 
Hedgehog, Notch and TGF-b/BMP pathways are frequently modulated 
in cancer by epigenetic mechanisms. 
Hedgehog (Hh) is a key signaling pathway for the regulation of 
embryonic development and tissue repair, mainly through the control of 
stem and progenitor cells (e.g. neural stem cells) and for the control of a 
number of genes involved in cell fate determination and stemness 
features. When hyperactivated by genetic and/or epigenetic alterations, 
Hh pathway promotes tumorigenesis in several tissues by subverting 
the regulation of stemness-determining genes overexpressed in that 
type of cancer. 
 
Normal Hh signaling 
 
Binding of Hh to its receptor Patched (Ptch-1) activates the 
transmembrane protein Smoothened (Smo), which subsequently 
activates the Gli family of transcription factors, leading to activation of 
target genes (Figure 52): 
 
Figure 52: Normal Hedgehog signaling pathway 
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Hedgehog signaling in cancer 
 
Aberrant Hh signaling occurs in some cases because of a ligand-
indipendent activativation of SMO due to a mutation in PTCH1 or in SMO 
(Figure 53a), but it generally happens through ligand-dependent 
mechanisms (Figure 53b,c). Increased Hh ligand expression leads to 
increased Hh signaling in the activated target cell. This can theoretically 
occur through either an autocrine mechanism (Figure 53b) where the 
malignant cells both secrete and respond to Hh ligand, or through a 
paracrine mechanism (Figure 53c) where the secreting cell and 
recipient target cell are different. Even if the autocrine mechanism has 
been reported for multiple tumor types, the currently overall favored 
mechanism is the paracrine model, based partly on evidence that tumor 
cells do not appear to respond to Hh ligand themselves[115].  
 
 
Figure 53: Hedgehog signaling in cancer 
 
One proposed explanation has been that tumor cells lack the primary 
cilium necessary for canonical Hh signaling through PTCH1 and SMO. 
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Hedgehog inhibitors 
 
On the base of the acquired knowledge concerning the signaling steps of 
the Hh signaling pathway, it is possible to identify different potential 
ways to inhibit this pathway in cancer. To date, the best-characterized 
approach is to target the SMO receptor with small molecule inhibitors, 
and many of such inhibitors are under clinical trial investigation.  
Alternatively, preventing SMO from converting from the inactive to the 
active form should also achieve the same result.  
The limitation with these two approaches is that they will fail if 
activation occurs by alteration of the signaling pathway downstream of 
SMO. 
Drugs that can interfere with the Hh signaling pathway downstream of 
SMO are therefore also of potential therapeutic benefit. 
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Cyclopamine 
 
The Veratrum alkaloid known as cyclopamine was the first agent that 
was found capable of disrupting the Hh signaling pathway[116]. 
Cyclopamine belongs to the family of jervine alkaloids, which constitute 
the majority of Veratrum secondary metabolites. The association of 
Veratrum Californicum to 
sheep congenital deformities 
during the 1950s raised the 
possibility that jervine 
alkaloids could be potent 
teratogens. Later studies 
confirmed that jervine and 
cyclopamine given during 
gestation can directly induce 
cephalic defects in lambs, 
including cyclopia. 
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Figure 55: Structure of jervine and cyclopamine 
 
Cyclopamine[117] was shown to be a potent antagonist of the Hh 
pathway, directly acting on the protein Smo, and has been shown to 
have antitumor activity in several xenograft models.  
Despite the attractive pharmacological profile of cyclopamine, its use as 
a systemic treatment may be limited by its poor aqueous solubility 
(∼5µg/ml) and stability in acid. In fact, cyclopamine readily converts to 
Figure 54: Veratrum Californicum 
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veratramine as a result of an acid-catalyzed opening of the 
spirotetrahydrofuran E ring followed by rapid aromatization of the D 
ring (Figure 56). Veratramine, while not acting as Hh antagonist, has 
been shown to interact with several other receptors and cause 
hemolysis. 
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Figure 56: Structure of cyclopamine and veratramine 
 
In order to obtained more stable  and soluble hedgehog inhibitors, many 
efforts have been made for the preparation of cyclopamine 
analogues[118][119].  
 
 Glycosidic derivatives: it is well known that sugars attached to 
small molecule-based drugs can dramatically influence 
pharmacodynamics and pharmacokinetics[120][121]. Recent 
studies revealed a set of nonmetabolic sugars able to improve 
the anticancer activity of a range of scaffolds[122][123][124]. This set 
includes both D- and L- enantiomers of aldopentoses, D-
glucurono-6,3-lactone and D-threose.  
Goff and Thorson reported the preparation of cyclopamine 
neoglycosides containing both metabolic and nonmetabolic 
sugars[125](Figure 57). 
 
Figure 57: General structure of neoglycosidic derivatives of cyclopamine 
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Both the kinds of sugars were able to increase the solubility of 
cyclopamine, but those containing non metabolic sugars induced 
a higher inhibition of cancer cell growth than the other ones.  
 
 Peptide-containing prodrugs: cyclopamine selectively inhibits the 
Hedgehog pathway. This pathway is highly activated in the 
cancer stem cell population, but it is also active in somatic stem 
cells, and this results in toxicity of cyclopamine towards non-
cancerous stem cells. In order to reduce this toxicity, one 
strategy could be to obtain a targeted delivery of cyclopamine to 
its site of action. 
In 2008[126] Khan and coworkers described a "prodrug" of 
cyclopamine in which the active agent was coupled to a peptide 
carrier that is a substrate for a prostate tissue-specific serine 
protease: prostate-specific antigen (PSA). PSA is expressed in a 
high level only in prostate cells, while in the blood circulation is 
present only in an inactive form.  
This kind of inactive prodrug should be non-toxic in the 
circulation and in PSA-negative tissues, but should become 
active when processed proteolytically by PSA. In this context, the 
authors prepared two "prodrugs" containing two different 
peptidic sequences (Figure 58). These derivatives were able to 
release cyclopamine when incubated in presence of PSA and 
possessed biological activity compared to the one of 
cyclopamine. 
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Figure 58: Peptidic derivatives of cyclopamine 
 
 Multiple-drug micelles: Kwon and coworkers recently[127] 
described the preparation of poly(ethylene glycol)-block-poly(ε-
caprolactone) (PEG-b-PCL) micelles loaded with cyclopamine 
(CYP), Paclitaxel (PTX) and Gossypol (GSP) (Figure 59).  
Gossypol is a polyphenolic compound able to inhibit anti-
apoptotic proteins, such as Bcl-2, Bcl-xL and Mcl-1. The 
interesting aspect of this delivery system is that all three 
anticancer drugs are poorly water-soluble and PEG-b-PCL 
micelles can deliver all three together. 
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Figure 59: Structure of paclitaxel, cyclpamine and gossypol 
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PEG-b-PCL micelles containing only PTX (30mg/Kg) were effective in 
delaying tumor progression during drug treatment, but after 
termination of the treatment the tumor started to regrow.  
On the other hand, 3-drug PEG-b-PCL micelles with PTX, CYP and GSP at 
30, 30, 30 mg/kg also prevented tumor progression but, after the 
second treatment, were able to stop the regrowth fro about two weeks. 
Even if this kind of delivery system gives some benfits, most of all 
concerning the toxicity of the vehicle, micelles shown to be quite 
unstable: in fact, part of the three drugs precipitated over a 24 h period. 
For this reason, the obtainment of stable micelles (or, in general, of 
assemblies) is one of the most important features do gain for this kind of 
treatment to be effective. 
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Squalene-based derivatives 
 
In order to overcome the problems connected to the instability and low 
water solubility of cyclopamine, we envisioned the possibility to 
prepare two squalene-cyclopamine conjugates, following the same 
strategy previously described for paclitaxel, podophyllotoxin, 
epothilone A and camptotecin (Figure 60): 
 
 
Figure 60: Structure of squalene-cyclopamine conjugates 14a-b 
 
This kind of conjugates should be able to self-assemble in water, thanks 
to the squalene tail, and, due to the EPR effect, to reach in a more 
selective way tumor tissues. 
As already described, once the nanoaggregates reach the tumor site, 
they could be internalized and then, in the presence of glutathione, the 
disulfide containing compound 14a should release cyclopamine. 
The derivatives were prepared following the pathway described in 
Scheme 7: 
103 
 
Scheme 7: Synthesis of cyclopamine-squalene conjugates 
 
In order to allow the hydroxy group to react as a nucleophile, we 
protected piperidine nitrogen with a Fmoc group, following a procedure 
described by Tremblay and coworkers[117]. N-Fmoc-protected 
cyclopamine was then coupled to 7a-b, prepared as already described 
using EDC.HCl/DMAP as activating system. In the end, the protecting 
group was removed by treatment with Et2NH in CH2Cl2. The final 
compounds were characterized by 1H- and 13C-NMR and ESI-MS spectra. 
Formulation as nanoparticles 
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Preparation: in order to allow the formation of nanoassemblies, the 
solvent displacement method was applied.  
In a typical procedure, 4 mg of the conjugate were dissolved in 1 ml of 
EtOH, the solution was added dropwise to 2 ml of MilliQ water and then 
the organic solvent was removed under reduced pressure, with 
subsequent formation of a nanoaggregate suspension at a final 
concentration of 2 mg/ml. 
Both the two compounds were able to self-assemble and the two 
suspensions were characterized to determine the mean diameter, the 
polydispersity index and the Z-potential. 
 
Characterization: 
 Dimensional analysis: mean diameter and dimensional homogeneity 
(polydispersity index) of nanoassemblies were determined with 
quasi-elastic light scattering (QELS) experiments, at a fixed angle of 
90°, using a 90 Plus Particle Size Analyzer (Brookhaven Instrument, 
Co.) 
The results we obtained are summarized in Table 7: 
 
Compound 
Mean Diameter  
(nm) 
Polydispersity 
Index 
14a 105.6 0.063 
14b 109.3 0.249 
 
Table 7: Mean diameter and polydispersity index for compounds 14a, b 
 
 Z-potential measurement: Unfortunately, we weren't able to obtain a 
precise measure of Z-potential values, in fact repeating the 
measurements we obtained values very different one from the other. 
This can be due to malfunctioning of the instrument or to intrinsic 
properties of the suspensions. In any case, the measurements are 
currently being repeating in our laboratories. 
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Release of cyclopamine 
 
In order to verify the stability of conjugates 14a, b in the presence of 
GSH we applied the same procedure we used for other disulfide-
containing compounds[69][70]. 
A solution of GSH (0.0058 mmol) in H2O (0.300 ml) was added to a 
solution of the 14a (0.0058 mmol) in MeOH (3 ml) and the reaction 
mixture was stirred at room temperature for 24 hours. A sample of the 
reaction mixture was submitted to an ESI-MS spectrometry analysis in 
order to detect the presence of one or more of the possible products, 
and possibly free cyclopamine (Figure 45).  
 
Figure 61: Possible products of the reaction of 14a with GSH 
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As a comparison, we effected the same reaction also with compound 
14b. 
As showed by ESI-MS analyses, in both the cases the peak of free 
cyclopamine (m/z: 412) was detected, while only for compound 14a we 
found also the peak of intermediate "A" (m/z: 513). 
This means that GSH could be involved in the release of cyclopamine 
from 14a, thus exploiting the presence of the disulfide bond; on the 
other hand, the presence in both the cases of cyclopamine coul be due to 
a low stability of our conjugates in solution or to a fragmentation of the 
molecular ion. 
In order to better elucidate the stability and releasing issues of our 
conjugates, all these aspects are currently under investigation in our 
laboratories. 
 
 
 
 
 
Biological evaluation 
 
A preliminary biological evaluation of the in vitro cytotoxicity of 
compounds 14a and 14b is currently under investigation in the 
laboratories of Prof. P. Sotiropoulou (Université Libre de Bruxelles). 
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Summary 
 
The results obtained with compounds 8-11a and 14a enlightened as an 
efficient release of parent drugs from conjugates can greatly improve 
the biological activity. In fact compound 8a possesses a cytotoxicity 
almost comparable to that of free paclitaxel. 
Using different kind of cleavable linkers it is possible to prepare a 
variety of conjugates, able to release drugs in different specific 
conditions, thus exploiting some intrinsic peculiarity of tumors. 
Thus, we decided to take into consideration also different linkers and 
mechanisms for a tumor-targeted drug release. 
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Section 3: Plasmin-activated tripeptidyl 
squalene derivatives 
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Introduction 
A persistent problem in cancer chemotherapy is the low therapeutic 
index of most anticancer drugs. An approach to overcome this problem 
is to design anticancer "prodrugs" which are inactive until locally 
activated by some tumor-associated enzyme[75]. 
Tumors that contain a high level of some specific enzyme could convert 
the prodrug into the pharmacologically active drug in the vicinity of the 
tumor[128][129]. In this purpose proteases, a number of which, such as 
plasmin, are known to participate and collaborate in tumor invasion and 
metastasis, are one of the most useful family of enzymes.  
 
Proteases 
 
Proteases are enzymes that perform proteolysis, thus effecting protein 
catabolism by hydrolysis of peptidic bonds. Proteases are currently 
classified into six groups: 
 
 Serine proteases; 
 Threonine proteases; 
 Cysteine proteases; 
 Aspartate proteases;  
 Glutamic acid proteases; 
 Metalloproteases. 
 
Serine proteases 
 
In particular, serine proteases use a serine residue as a nucleophile to 
attack the carbonyl group of a peptidic bond, that thus is cleaved. 
On the base of their structure they can be further divided in two groups: 
 
 Chymotrypsin-like serine proteases, then subdivided in 
chymotrypsin-, trypsin- and elastase-like; 
 Subtilisin-like serine proteases. 
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The familiy of trypsin-like serine proteases contains more than 70 
members, involved in many physiological and pathological processes. 
Although all of them cleave their substrates after the basic amino acids 
arginine or lysine, there are big differences in their substrates 
specificities: in fact, some of them are highly specific towards very few 
natural substrates, while others can hydrolize a variety of substrates. 
 
Functions of proteases 
 
Proteases are thought to play a primary role in the dissolution of the 
extracellular matrix that is necessary for the passage of migrating cells 
through tissue barriers in a diversity of biological processes. The 
migration and invasion of cells in physiological situations, such as 
embryo morphogenesis, angiogenesis, wound healing and other 
processes involving tissue destruction and remodelling, is of limited 
extent and duration and therefore must be subject to strict regulation to 
initiate, localize, and terminate the proteolytic activity. The same 
proteolytic enzyme systems are also thought to contribute to the 
invasive properties and metastatic potential of malignant tumor cells.  
Among the proteases involved in these processes, plasmin and its 
generation by plasminogen activators plays a key role. 
  
Plasmin 
 
The plasmin system is recognized to play a key role in tumor invasion 
and metastasis by its matrix degradating activity and its involvement in 
tumor growth factor activation and angiogenesis 
plasmin catalyzed the breakdown of extracell
thus, contributes to migration, invasion and metastasis of tumor cells 
[131]. 
In the body plasmin is predominantly present in its inactive pro
form plasminogen. Active plasmin is formed locally at or near the 
surface of tumor cells by urokinase
produced by cancer and/or stroma cells 
Plasmin activity is kept localized because cell
activate cell-bound plasminogen into active p
bound. Active urokinase and active plasmin do not occur in the blood 
circulation because they are rapidly inhibited by PAI
antiplasmin respectively. 
 
 
Figure 62: Schematic illustration of the f
plasminogen and proteolysis of plasmin substrates
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Many tumor cell lines have significantly higher u-PA level than that of 
their normal counterparts[133] and u-PA was shown to be correlated with 
invasive behavior and to be strong prognostic factors for reduced 
survival and increased relapse in many types of tumors[134]. 
Thus, plasmin is a very promising enzyme for exploitation in a tumor-
specific prodrug approach because the proteolytically active form is 
localized at the tumor level. Moreover, it is possible to design highly 
specific substrates for plasmin incorporating a short peptide sequence 
that can be selectively cleaved by plasmin. 
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Plasmin-activated prodrugs 
 
The first prodrugs designed for specific activation by plasmin were 
reported by Katzenellenbogen and his coworkers in the beginning of 
'80s[135][136][137]. In the beginning they prepared two classes of 
"prodrugs", coupling two anticancer agents to a tripeptidic sequence, 
with the aim of obtaining inactive peptidyl derivatives selectively 
activated by plasmin in the proximity of tumor cells. In this purpose, 
they chose as anticancer agents acivicin and phenylenediamine 
mustard: 
 
 
 
Figure 63: Acivicin (a) and its peptidyl derivative (b); phenylenediamine mustard (c) 
and its peptidyl derivative (d) 
 
Interestingly, these compounds showed a 5- to 7-fold increase in 
selectivity compared to the free drugs and the addition to the cell 
medium of a plasmin inhibitor (p-nitrophenyl p'-guanidinobenzoate) 
dramatically reduced the activity (dose for 50% effect increased 9-
fold)[135][136]. On the base of the evidences obtained for compounds b and 
d, the authors decided to prepare the same peptidyl derivative of 
doxorubicin[137]. 
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Figure 64: Doxorubicin (e) and its peptidyl derivative (f) 
 
Despite an increase in the in vitro selectivity compared to the free drug 
and a decrease in the in vivo toxicity, this compound showed a poor 
potency, thus limiting its utility. The authors hypotesized that this could 
be due to a steric hindrance limiting the cleavage by plasmin, and that 
this could be overcome by inserting a spacer between the peptide and 
the drug moiety[138][139]. 
For this reason they prepare a small collection of conjugates, using 
different spacers and drugs (Figure 65).  
Noteworthy, the incorporation of self-immolative 1,6-elimination 
spacers in plasmin activated prodrugs resulted in an increased 
enzymatic activation rates (up to 10-fold higher) due to a facilitated 
proteolytic cleavage. 
In particular these prodrugs, while showing a decrease in the 
cytotoxicity in different normal cell lines, gave promising results when 
tested in cell cultures transfected with wildtype u-PA. In fact, they 
showed the same cytotoxic effect than the free drug, indicating a 
complete conversion of the prodrug by plasmin. Furthermore, the 
addition of the plasmin inhibitor trasylol, which had no effect on free 
drugs treated cells, drastically increased the ID50 values in the u-PA 
transfected cells[140][141][142]. 
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Figure 65: Doxorubicin (g, h), paclitaxel (i, j) and camptothecin (k) peptidyl derivatives 
containing a spacer 
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Aim of the work 
On the base of the results obtained for disulfide-containing squalene 
derivatives and taking into account the interesting applications of 
plasmin in the activation of prodrugs by cleavage of a tripeptidic 
sequence, we envisioned the possibility of preparing a "2nd generation" 
collection of drug-releasing squalene conjugates (Figure 66): 
 
 
Figure 66: Tripeptidyl drug-squalene conjugates 
 
These compounds contain a D-Ala-Phe-Lys sequence that is a substrate 
for the protease activity of plasmin and acts like a trigger: in fact, after a 
1,6-elimination of the spacer, free drugs could be released (Scheme 8): 
 
Scheme 8: Release of the drug unit from our  
tripeptidyl squalene conjugates 
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We individuated four different portions, deriving from three main 
disconnections: the peptide, the 1,6-elimination spacer, the squalene 
moiety and the active drug (Figure 67). 
 
 
 
Figure 67: Retrosynthetic analysis 
 
 
Synthetic strategy 
 
The synthetic pathway we followed for the preparation of the 
tripeptidyl portion is summarized in Scheme 9.  
Nε-Z-L-lysine methylester hydrochloride, obtained by treatment of  Nε-Z-
L-lysine with SOCl2 in MeOH, was coupled to N-Boc-L-phenylalanine 
using EDC.HCl/DMAP as activating system. Dipeptide 18 was then N-
deprotected with TFA in CH2Cl2 affording 19 that was coupled to N-Boc-
D-alanine in the presence, also in this case, of EDC.HCl/DMAP. The 
carbobenzyloxyl moiety was then cleaved by hydrogenation involving 
Pd/C 10% weight as a catalyst. In the end, the reaction of the tripeptidyl 
intermediate 22 with Boc2O and NaOH 5% led to the formation, after pH 
adjustment to 5, of the desired compound 23. 
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Scheme 9: Synthesis of compound 23 
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Once the tripeptidyl portion was obtained, it was coupled to the 
ethylenediamine mono-Cbz-protected spacer 25, and then the Cbz 
protecting group was cleaved by catalytic hydrogenation. Compund 27 
underwent a reductive amination with 4 with NaBH(OAc)3, leading to 
intermediate 28. Since 27 is a primary amine, it was necessary to use an 
eccess of it respect to the aldehyde (molar ratio: 3:1), in order to 
minimize the amount of the product deriving from a double alkylation ( 
Scheme 10). 
 
Scheme 10: Synthesis of compound 28 
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Compound 28 was then used for the synthesis of three tripeptidyl drug-
squalene conjugates following the pathway depicted in Scheme 11. In 
detail, compound 28 reacts with a molecule of drug previously activated 
by p-nitrophenyl-chloroformate (29-31). After carbamates formation, 
the Boc moieties are cleaved by treatment with a saturated solution of 
HCl in MeOH, thus obtaining the desired products 35-37. 
 
 
Scheme 11: Synthesis of tripeptidyl drug-squalene conjugates 35-37 
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On the base of the poor stability of epothilone A-derived disulfide 
containing squalene conjugates described in Section 2, we decided to 
prepare only three final conjugates, using paclitaxel, podophyllotoxin 
and camptothecin as active drugs (Figure 68). 
 
 
Figure 68: Structure of compounds 35-37 
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Nanoparticle formation and characterization 
Compounds 35-37 have been formulated using the same protocol than 
disulfide-containing conjugates (see Section 2). 
Interestingly, tripeptide-containing squalene conjugates didn't show the 
ability to self-assemble in water, but they resulted completely soluble in 
an aqueous medium. This was totally unexpected, since all the 
compounds containing a squalene tail prepared until now, even those 
containing a polar counterpart, were able to nanoprecipitate. 
As an explanation, we hypothesized that the presence of a polar 
tripeptidic chain containing two hydrochloride amino groups led to a 
dramatic increase in the water solubility, so that the lipophilic squalene 
tail wasn't able to allow the formation of nanoassemblies.  
This could be overcome by eliminating the two hydrochloric acid 
molecules, but the small quantities of conjugates we were handling 
didn't allow us to. 
Furthermore, since the nature of the aqueous medium influences the 
nanoprecipitation process, it could be possible that, using different 
buffer solutions, the optimal conditions for the formation of 
nanoassemblies could be found. 
All these aspects are currently under investigation in our laboratories. 
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Incubation with plasmin 
In order to verify the ability of compounds 35-37 to release the 
corresponding parent drug, we incubated 35-37 with human plasmin 
(purchased by Sigma-Aldrich) following a procedure described by de 
Groot[141]. 
In this purpose we incubated the conjugates at a concentration of 200 
μM in 0.1 M ammonium acetate buffer (pH 7.3) in the presence of 100 
μg/ml human plasmin.  
As a comparison, we prepared also the same solution but without 
plasmin (blank). 
Aliquots of 50 μL at different times were submitted to ESI-MS analysis, 
in order to detect the possible peak of released free drugs. 
Unfortunately, the results we obtained are very difficult to explain, being 
very different from one conjugate to another: 
 
 compound 35 (Paclitaxel derivative): we were able to see the 
peak of free paclitaxel (m/z = 876.9) in both the sample relative 
to incubation with and without plasmin; 
 compound 36 (Podophyllotoxin derivative): we weren't able to 
detect any significant peak, probably because of a low stability of 
the conjugate in the buffer solution; 
 compound 37 (Camptothecin derivative): we detect in both the 
reaction with and without plasmin peaks attributable to 
tripeptidyl and squalene fragmentations, but not to free 
camptothecin. Suspecting eventually released camptothecin was 
not stable in the reaction conditions, we also incubated it in the 
same buffer solution used for reaction with plasmin. ESI-MS 
analysis clearly revealed the peak of camptothecin molecular 
ion. 
 
We are currently investigating other possible reaction conditions (using 
different buffer solutions and analysis techniques) in order to determine 
whether the release of free drugs actually takes place or not and to find 
a way to favor it.  
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Biological evaluation 
Compounds 35-37 were submitted to a preliminary evaluation of their 
cytotoxicity against A549 cell lines in collaboration with Dr. Damia 
(Istituto Mario Negri, Milano). Unfortunately they displayed a low 
cytotoxic activity, as enlightened by the results summarized in Table 8: 
Compound IC50 (μM) 
35 >5 
36 >5 
37 >5 
 
Table 8: IC50 values (μM) of compounds 35-37 
 
Since the low biological activity could be due to a not efficient release of 
the active drugs in vitro, we are currently evaluating the possibility to 
firstly incubate cells with human plasmin (purchased by Sigma-Aldrich) 
before treatment with our conjugates, in order to favor the cleavage of 
the peptidiyl sequence.  
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Summary 
 
The results obtained with conjugates 35-37 apparently suggest that the 
addition of a squalene tail to a class of compounds that have been 
demonstrated able to release free drug units when incubated with 
plasmin is not a useful approach for improving biological activity. 
Indeed, squalene moiety could cause a steric hindrance that doesn't 
allow plasmin to cleave the tripeptidy sequence and, without an efficient 
release mechanism, the cytotoxicity of the conjugates results lowered 
respect to the parent drug. 
Anyway, the tripeptidyl sequence could allow a better bioavailability of 
drugs (as demonstrated by the water-solubility of compounds 35-37), 
while squalene could favor the passage through cell membranes, thus 
improving the biological profile of a drug.  
For these reasons we are currently taking into consideration these 
issues, in order to better understand the mechanism of action of plasmin 
and in which conditions it could be favored.  
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Section 4: Heterogeneous  
fluorescent nanoparticles:  
FITC-squalene conjugates 
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Introduction 
 
Besides the improvements due to attaching a squalene tail to an active 
drug, that thus becomes able to self-assemble in water, another 
interesting aspect is to study the mechanisms of cellular uptake of 
nanoparticles, once they are formed. 
To do this, it would be necessary to label nanoparticles in some way, in 
order to elucidate how they interact with cell membranes.  
Thus, we envisioned the possibility to prepare a fluorescent derivative 
of squalene able to form biocompatible fluorescent nanoparticles, for 
studying their mechanisms of internalization and their localization 
inside the cell.  
An interesting feature of this system is the fact that the fluorescent is 
not physically adsorbed on a matrix or included in a system but is 
covalently linked to squalene, thus resulting in a higher stability and 
biocompatibility of the materials.  
This kind of approach could be applied also to diagnostic purposes, for 
the localization of agents in live beings. 
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Fluorescence spectroscopy 
  
The use of fluorescence spectroscopy allows highly sensitive 
measurements with instrumentation exploiting different sensing modes, 
like intensity, lifetime and polarization detection. In addition, the 
combination of those methodologies with the high spatial resolution of 
fluorescence microscopy has enabled the intracellular monitoring of 
many different species for medical and biological purposes[143][144][145].  
Radioactive molecular imaging[146], magnetic resonance imaging[147][148], 
and optical imaging[149] have been recognized as powerful techniques in 
this field. Easy manipulation and high sensitivity make optical imaging 
the most widely used technique. 
Fluorescent methods based on organic dyes are simple, diverse and 
nondestructive methodologies and their applications depend on the 
nature of the molecule they are bound to, thus being useful not only as 
diagnostics but also as therapeutics. 
However, these dyes suffer from intrinsic limitations, in fact they show: 
 
 low absorption coefficients and weak signals that normally 
reduce the sensitivity and response of the applications; 
 poor photobleaching resistance that limits their use in long-term 
tracking; 
 short fluorescent lifetimes[150].  
 
Moreover, when their application is the intracellular detection, 
researchers are still dealing with other drawbacks, such as the toxicity 
of some organic dyes, their aggregation inside tissue or cells, and their 
interaction with cell components that might lead to the quenching of the 
fluorescence.  
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Fluorescein 5(6)-isothiocyanate derivatives 
 
Among fluorescent compounds, fluorescein presents a number of 
attractive features:  
 
 its excitation wavelength (λ = 488 nm) does not interfere with 
the absorbances  of cellular proteins; 
 it has been extensively used in the preparation of fluorescent 
sensors[151][152][153]; 
 it is easily accessible; 
 it does not require sophisticated microscopic instruments. 
 
Our research group recently prepared[154] a small collection of 
fluorescein 5(6)-isothiocyanate (FITC) derivatives containing a tubulin 
binder unit (deacetylthiocolchicine, paclitaxel and cephalomannine), 
with the aim of obtaining new fluorescent dyes that can secure a direct 
assay to evidence the tubulin/microtubules network both in cells and in 
vivo and to overcome the invasive techniques of transfection or 
microinjection ( 
Figure 69). In fact, in light of our interests concerning the biology of 
tubulins and their implication in cancer and neurodegenerative 
diseases[67][69][70], fluorescent dyes specific for tubulin for in vitro and in 
vivo imaging studies could be very useful. 
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Figure 69: Structures of deacetylthiocolchicine and its fluorescent 
 derivative a, paclitaxel and its fluorescent derivative b,  
cephalomannine and its fluorescent derivative c 
 
Unfortunately, taxane derivatives b and c were unstable. Compound a 
was minimally able to inhibit tubulin polymerization, was cell 
permeable and able to bind to microtubules in a cellular context 
requiring a dynamic exchange between free and polymerized tubulin, 
thus meeting some of the demanding requirements for a new 
fluorescent dye that can secure a direct assay to evidence the 
tubulin/microtubule network in cells. 
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Fluorescent delivery systems 
 
Besides the possibility of finding new fluorescent molecules, the recent 
advances in nanotechnology and nanomaterials have been integrated 
into analytical chemistry for the preparation of novel fluorescent 
delivery systems[155]. 
In fact, nanoparticle systems can provide advantages over traditional 
approaches in term of sensitivity, stability, and capability for 
multiplexing[156]. Instead of using single organic dye probes, these 
organic fluorophores have been encapsulated in a particle matrix: these 
particles are brighter than single dyes since one particle contains 
several fluorescent molecules, and they also are more photostable, since 
the entrapment enhances the stability and biocompatibility of the 
fluorophores.  
The particle sizes generally range from 2 nm to several  μm, even though 
the majority is within the nm scale. The small size of nanoparticles 
provides an opportunity for high signal to noise ratio response and 
signal amplification, therefore improving the analytical sensitivity and 
the response time. Importantly, their molecular size minimizes physical 
perturbation of living cells, and also provides high spatial resolution.  
The first applications of fluorescent nanoparticles for intracellular 
measurements were for the labeling and imaging of cells, bacteria, cell 
components and tissues, for the exploring of intracellular processes[157]. 
Later, other important intracellular applications were their use for 
diagnosis and therapeutics, especially for the recognition of cancer cells 
in vivo[158]. Finally, during the last years, the application of fluorescent 
nanoparticles in the field of intracellular sensing is being examined for 
the real time quantification of intracellular analyte concentration[159], 
which can give more insights into the chemical microenvironment on 
the sub-cellular level. 
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Recent applications of fluorescent nanoparticle delivery systems 
 
In the last years many research groups reported the use of nanoparticle 
delivery systems as carriers of fluorescent dyes, such as the two 
following examples: 
 
 Bovin serum albumin nanoparticles: Patel and coworkers 
described[160] the preparation of glutathione(GSH)-containing 
bovin serum albumin nanoparticles (Figure 70) encapsulating, 
as fluorescent dye, molecules of fluorescein sodium salt. 
Since GSH is among the few 
molecules (such as O2, H2O 
and CO2) able to pass 
through the blood brain 
barrier (BBB), these 
nanoparticle were able to 
reach the brain, and this 
was confirmed by 
exploiting the presence of 
fluorescent molecules. 
 
 
 
 Mesoporous silica nanoparticles: Yuan and coworkers prepared a 
different kind of delivery system based on mesoporous silica 
nanoparticles covalently bound to paclitaxel by a disulfide bond 
and containing FITC molecules[161]( 
 Figure 71).  
These kind of system present interesting features since: the 
formulation as nanoparticles allow a selective delivery to tumor 
tissues, the disulfide bond connecting paclitaxel to silica can be 
cleaved by the high  concentration of GSH in some kind of tumor 
cells and the presence of FITC makes nanoparticles be 
fluorescent, thus allowing the study of the internalization 
mechanisms. 
Figure 70: SEM image of glutathione- 
conjugated fluorescein sodium-loaded 
 BSA nanoparticles 
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Figure 71: Confocal laser scanning microscopy (CLSM) images of HeLa cells incubated 
with 100 μg/mL of the FMSN-PTX conjugate for 4 h. (Left) Spotlike green fluorescent 
images showing internalized FMSN-PTX conjugates. (Middle) Differential interference 
contrast (DIC) images. (Right) Merged image of DIC and green. 
 
 Ruthenium polypyridyl squalene derivatives: with the aim of 
expanding the squalenoylation platform (see Section 1) to 
include novel cell-imaging probes, Dosio and coworkers 
described  the conjugation of the bulky complex [Ru(II) bis(2,2'-
bipyridine)-{1-methyl-2(4-methylpyridin-2-yl)-benzoimidazo-
le}](PF6)2 to squalene[162]: 
 
 
Figure 72:  Dosio's [Ru(II) bis(2,2'-bipyridine)-{1-methyl-2(4-
methylpyridin-2-yl)-benzoimidazo-le}](PF6)2 - squalene conjugate 
 
This compound was capable of self-assembling in water, 
underwent cellular uptake and diffusion, and didn't exercise a 
significant toxicity. 
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Aim of the work 
 
On the base of our experience in the preparation of fluorescent tubulin 
binders and in the preparation of squalene-based nanoparticles, we 
envisioned the possibility to combine these two different approaches in 
order to obtain a new kind of nanoassemblies containing both a 
fluorescent squalene derivative and a drug-squalene conjugate to better 
investigate the mechanisms of internalization of drug-squalene 
nanoparticles. 
For this preliminary study, we chose to use as squalene-drug conjugate 
compound 16 (PTX-Sq) and to link a FITC molecule to a squalene tail to 
obtain the fluorescent derivative 17 (Figure 73): 
 
 
Figure 73: Structures of PTX-Sq and FITC-Sq 
This kind of co-nanoassemblies could have all the advantages of the 
application of nanotechnology to optical imaging and, in addition, could 
exploit the biocompatibility of squalene. Furthermore, since the 
fluorescent dye is covalently linked to squalene, and not simply 
incapsulated in a polymeric matrix, the resulting co-nanoassemblies 
could be more stable.  
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Synthetic strategy 
 
PTX-Sq was prepared following a procedure described by Dosio and 
coworkers[55]. Compound 4 was oxidized to the corresponding 
carboxylic acid 15 by treatment with H2SO4/Na2Cr2O7 and then 
condensed to paclitaxel using EDC.HCl/DMAP as activating system 
(Scheme 12): 
 
 
Scheme 12: Synthesis of PTX-Sq (16) 
 
Compound 17 (FITC-Sq) was prepare by reaction of fluorescein5(6)- 
isothiocyanate with the anion of compound 5, generated in situ by 
treatment with NaH (Scheme 13). 
 
 
Scheme 13: Synthesis of FITC-Sq (17) 
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Fluorescent nanoparticles 
 
In order to verify the ability of compound 17 (FITC-Sq) to form 
nanoassemblies and of compounds 16 and 17 to form homogeneous 
mixed nanoparticles, we prepared 5 different nanosuspensions applying 
the same procedure used for the other drug-squalene conjugates:  
 
A) FITC-Sq (2 mg/ml); 
B) PTX-Sq (2 mg/ml) : FITC-Sq = 10 : 1; 
C) PTX-Sq (2 mg/ml) : FITC-Sq = 20 : 1; 
D) PTX-Sq (2 mg/ml) : FITC-Sq = 30 : 1; 
E) PTX-Sq (2 mg/ml). 
 
In the case of suspensions B, C and D, the final concentration (2 mg/ml) 
is referred to PTX-Sq, while the amount of FITC-Sq was calculated 
considering the molar ratios PTX-Sq : FITC-Sq (10:1, 20:1, 30:1). 
 
. 
 
 
 
 
 
 
 
In each case the formation of nanoassemblies was verified. The 
nanosuspensions were then characterized, in order to determine mean 
diameter, polydispersity index and Z potential. The results we obtained 
are summarized in Table 9.  
A B E C 
(a) (b) 
Figure 74: Schematic representation (a) and picture (b) of the five mixtures 
D 
H2O (HPLC grade) 
PTX-Sq in MeOH (HPLC grade) 
FITC-Sq in MeOH (HPLC grade) 
A B C D E 
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Unfortunately, we weren't able to obtain a precise measure for Z 
potential of most of the suspensions, but values very different one from 
the other (all the measurements were always repeated thrice). This 
could be due to intrinsic factors of our nanoparticles or to a 
malfunctioning of the instrument we used. 
Even if the mean diameter of nanoparticles in sample B was lower than 
in sample A, it is possible to see that, decreasing the amount of SB213 in 
the mixture, the mean diameter of nanoparticles increased towards the 
value of sample E. 
  
Compound 
Mean 
Diameter 
(nm) 
PI 
Z potential 
(mV) 
FITC-Sq (A) 196.4 0.232 -19.91 
PTX-Sq: FITC-Sq  10:1 (B) 149.4 0.147 n.d. 
PTX-Sq: FITC-Sq  20:1 (C) 171.9 0.179 n.d. 
PTX-Sq: FITC-Sq  30:1 (D) 225.4 0.190 n.d. 
PTX-Sq (E) 231.6 0.270 n.d. 
Table 9: Mean diameter, polydispersity index and 
Z potential of the five mixtures 
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Fluorescence emission 
In order to verify the relationship between the amount of FITC 
derivative and the fluorescence emission of the mixtures and the 
dependence on the nature of the samples (solutions or 
nanosuspensions), we measured the fluorescence emission using a 
Spectrofluorometer FP-750 (Jasco).  
For a better measurement nanoparticle samples were diluted with 
water (HPLC grade) and pure FITC-Sq was dissolved in MeOH (HPLC 
grade) in order to have the main component of the mixture at a fixed 
concentration. The results we obtained are summarized in the following 
graphs. 
 
 Graph A: FITC-Sq (17) at different concentrations (samples as 
nanoparticles). Samples with higher amounts of FITC-Sq possess 
a higher fluorescence emission. 
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 Graph B: PTX-Sq at a fixed concentration (20 μM) with different 
amounts of FITC-Sq compared to FITC-Sq 20 μM (samples as 
nanoparticles). Also in this case, samples with higher amounts of 
FITC-Sq possess a higher fluorescence emission. 
 
 
 Graphs C, D and E: samples with different amounts of FITC-Sq (as 
nanoparticles) were compared to samples containing the same 
amounts of FITC-Sq but in solution. Noteworthy, the samples of 
nanosuspensions displayed a higher emission of fluorescence 
than the corresponding solutions and, at each value of FITC-Sq 
concentration, the mixture of PTX-Sq and FITC-Sq displayed a 
higher emission than FITC-Sq alone. 
This can be explained by the fact that the more hydrophobic the 
environment is, the higher the emission: thus, a nanosuspension 
results to be a more hydrophobic environment than a 
methanolic solution even if the sample is diluted with water. 
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Moreover, the presence of PTX-Sq in a 10:1 ratio respect to 
FITC-Sq further increase the  hydrophobicity of the system. 
 
 
 
 
Graph A: Fixed FITC-Sq concentration: 2 μM 
 
 
 
 
 
Graph B: Fixed FITC-Sq concentration: 1 μM 
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Graph C: Fixed FITC-Sq concentration: 0.67 μM 
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In live evaluation 
 
To verify the ability of our nanosuspensions to cross cell membranes 
monitored their internalization kinetics by fluorescent microscopy 
experiments. 
A549 cells were incubated with nanosuspensions containing both PTX-
Sq and FITC-Sq at two different molar ratios (10:1 and 30:1) and then 
various images have been taken at different times (10, 30 and 60 min).  
For these measurements nanosuspensions have been prepared applying 
the solvent displacement method (concentration of PTX-Sq: 2 mg/ml), 
then they were diluted ten times, obtaining for FITC-Sq the following 
concentration values: 
 
 Mixture B (PTX-Sq/FITC-Sq 10:1): 13.8 μM 
 Mixture D (PTX-Sq/FITC-Sq 30:1): 4.6 μM 
 
As shown in Figure 75, FITC-Sq (in green) accumulates in the 
perinuclear region of cells incubated with samples at both the two molar 
ratios,  whereas in the case of 30:1 mixture the signal is weaker (even 
still present). 
Furthermore, it is also possible to recognize some intact nanoparticles 
(fluorescent spherical spots are evident inside cells), with mean 
diameters similar to those measured by QELS. 
These results strongly indicate that PTX-Sq/FITC-Sq co-nanoassemblies 
are internalized in cultured cells. 
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The interaction of our nanoparticles with microtubules is currently 
under investigation in the laboratories of Dr. Cappelletti (Università 
degli Studi di Milano, Dipartimento di Biologia).  
Figure 75: Right columns show actin filaments (red) and nuclei (blue), whereas 
white lines in the left columns mark the cell boundaries. Top row (Control) shows 
A549 cell that were not incubated with PTX-Sq/FITC-SQ co-nanoassemblies.  
Scale bar = 20 µm. 
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Section 5: Summary 
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Summary and future perspectives 
The work effected during this three-year project confirmed the utility of 
squalene in modulating the biological profile of active drugs and showed 
how this platform can be improved by including drug-releasing linkers 
in squalene derivatives.  
In this thesis we described two different approaches do allow drug 
release from squalene conjugates, but to them many others could be 
added by changing the mechanism of release. 
Furthermore, we also illustrated the preparation and characterization of 
a fluorescent squalene conjugate that resulted very promising for the 
study of nanoparticles internalization mechanisms by fluorescence 
spectroscopy. This approach can be extended also to co-
nanoprecipitation with other squalenoylated drugs and drug-releasing 
squalene conjugates, with a variety of applications. 
Another interesting aspect could be the preparation of different kinds of 
heterogeneous squalene nanoparticles for combined chemotherapy. 
All these issues will be carried on by our research group in the next 
months. 
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Section 6: Experimental Procedures 
  
154   
 
  
155 
Chemistry 
 
General 
 
Thin-layer chromatography (TLC) was performed on Merck precoated 
60F254 plates. Reactions were monitored by TLC on silica gel, with 
detection by Uv light (λ = 254 nm) or by charring with 1% 
permanganate solution. Flash chromatography was performed using 
Silica gel (240-400 Mesh, Merck). NMR spectra were recordered with 
Brucker 300 and 400 MHz spectrometers. Chemical shifts are reported 
in parts per million (δ) downfield from tetramethylsilane (TMS). EI mass 
spectra were recorded at an ionizing voltage of 6 kEv on a VG 70-70 EQ. 
ESI mass spectra were recorded on FT-ICR APEXII. Specific rotations 
were measured with a P-1030-Jasco polarimeter with 10 cm optical 
path cells and 1 ml capacity (Na lamp, λ = 589 nm). 
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Synthesis of 2 
 
 
 
To a solution of Squalene (1, 4.290 g, 0.010446 mol) in THF (30 ml) H2O 
(5 ml) is added and then THF dropwise to obtain a clear solution. N-
bromosuccinimide (2.231 g, 0.012535 mol) is added portionwise and 
the reaction mixture is stirred at room temperature for 3h. The solvent 
is removed under reduced pressure, brine (100 ml) is added and 
extracted with AcOEt (5x20 ml). The organic layers are dried over 
Na2SO4 and the solvent is removed under reduced pressure. The crude is 
purified by flash chromatography (CH2Cl2:Hex 1:1) to obtain 2 as a pale-
yellow oil (1.652 g, Yield: 31%). 
 
1H-NMR (CDCl3, 400 MHz): δ(ppm)= 5.10-5.25 (m, 5H); 4.01 (dd, J = 
11.3 Hz, J = 1.9 Hz, 1H); 2.32-2.35 (m, 1H), 1.95-2.17 (m, 18H); 1.77-1.88 
(m, 1H); 1.70 (s, 3H); 1.63 (bs, 15H); 1.37 (s, 3H); 1.36 (s, 3H). 13C-NMR 
(CDCl3, 100 MHz): δ(ppm)= 135.11; 134.89; 132.97; 131.24; 126.03; 
124.47; 124.26 (3C); 72.44; 71.01; 39.73 (3C); 38.18; 32.17; 28.28 (3C); 
26.68 (2C); 25.75 (3C); 17.68; 16.03 (3C); 15.85. APCI-MS: m/z 507.3 
[M]+. 
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Synthesis of 3 
 
 
 
To a solution of 2 (1.652 g, 0.003258 mol) in MeOH (60 ml) K2CO3 
(0.898 g, 0.006517 mol) is added and the reaction mixture is stirred at 
room temperature for 2 h, then concentrated under reduced pressure. 
H2O (120 ml) is added and extracted with AcOEt (4x30 ml). The organic 
layers are dried over Na2SO4 and the solvent is removed under reduced 
pressure to obtain 3 as a yellow oil (1.360 g, Yield: 98%) without any 
further purification. 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 5.06-5.17 (m, 5H); 2.69 (t, J = 6.1 
Hz, 1H); 1.95-2.19 (m, 20H); 1.68 (s, 3H); 1.60 (s, 3H); 1.58 (bs, 12H); 
1.28 (s, 3H); 1.24 (s, 3H). 13C-NMR (CDCl3, 100 MHz): δ(ppm)= 135.06; 
134.89 (2C); 133.96; 131.18; 124.93; 124.26 (4C); 64.17; 58.27; 39.72 
(3C); 36.31; 28.25 (2C); 27.46; 25.69; 24.89 (2C); 18.72; 17.67; 16.00 
(3C). APCI-MS: m/z 427.3 [M+1]+. 
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Synthesis of 4 
 
 
 
To a solution of H5IO6 (1.379 g, 0.006058 mol) in H2O (5 ml) a solution 
of 3 (1.434 g, 0.003366 mol) in dioxane (12 ml) is added and the 
reaction mixture is stirred at room temperature for 2h. H2O (150 ml) is 
added and extracted with AcOEt (3x40 ml). the organic layers are 
washed with brine (100 ml) and H2O (100 ml), then dried over Na2SO4 
and concentrated under reduced pressure to obtain 4 as a pale yellow 
oil (1.111 g, Yield: 86%) without any further purification. 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 9.73 (s, 1H); 5.06-5.13 (m, 5H); 
2.49 (t, J = 7.1 Hz, 2H); 2.30 (t, J = 7.1 Hz, 2H); 1.97-2.10 (m, 16H); 1.67 
(s, 3H); 1.55 (bs, 15H). 13C-NMR (CDCl3, 75 MHz): δ(ppm)= 202.65; 
135.11; 134.88; 134.77; 132.86; 131.23; 125.41; 124.52; 124.37; 124.25 
(2C); 67.06; 42.14; 39.73 (2C); 39.51; 31.83; 28.24 (2C); 26.73; 26.62; 
25.68 (2C); 17.66; 16.01 (3C). APCI-MS: m/z 385.3 [M+1]+. 
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Synthesis of 5 
 
 
 
To a solution of 4 (1.111 g, 0.002893 mol) in MeOH (45 ml) NaBH4 
(0.055 g, 0.001446 mol) is added portionwise and the reaction mixture 
is stirred at room temperature for 1 h. HCl 1M is added to quench the 
unreacted NaBH4. The solvent is the removed under reduced pressure, 
H2O (150 ml) is added and extracted with AcOEt (3x40 ml). the organic 
layers are dried over Na2SO4 and concentrated under reduced pressure 
to obtain 5 as a colorless oil (1.016 g, Yield: 91%) without any further 
purification. 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 5.08-5.13 (m, 5H); 3.61 (t, J = 6.3 
Hz, 2H); 1.99-2.08 (m, 18H); 1.78-1.85 (m, 2H); 1.67 (s, 3H); 1.59 (s, 
15H). 13C-NMR (CDCl3, 75 MHz): δ(ppm)= 135.11; 134.92 (2C); 134.54; 
131.24; 125.83; 124.42 (2C); 124.26 (2C); 62.80; 39.72 (3C); 35.99; 
30.73; 28.24 (2C); 26.60 (3C); 25.67 (2C); 17.66; 15.99 (3C). APCI-MS: 
m/z 387.3 [M+1]+. 
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Synthesis of 7a 
 
 
To a solution of 5 (0.660 g, 0.001706 mol) in dry CH2Cl2 (18 ml) 
dithiodibutyric acid (6a, 0.812 g, 0.003411 mmol), EDC.HCl (0.393 g, 
0.002047 mol) and DMAP (0.146 g, 0.001194 mmol) are added and the 
reaction mixture is stirred at room temperature for 24 h. HCl 1M (15 ml) 
is added and extracted with CH2Cl2 (5x5 ml). The organic layers are 
dried over Na2SO4 and the solvent is removed under reduced pressure. 
The crude is purified by flash chromatography (AcOEt/Hex) to obtain 7a 
as a colorless oil (0.596 g, Yield: 58%). 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 5.06-5.12 (m, 5H); 4.03 (t, J = 6.0 
Hz, 2H); 2.68-2.74 (m, 4H); 2.40-2.51 (m, 4H); 1.99-2.07 (m, 22H); 1.71-
1.79 (m, 2H); 1.68 (s, 3H); 1.59 (s, 15H). 13C-NMR (CDCl3, 75 MHz): 
δ(ppm)= 178.0; 173.1; 135.1; 134.9; 133.6; 125.1; 124.3 (4C); 64.3; 39.7 
(3C); 37.8; 37.6; 35.8; 32.6; 32.1; 28.2 (3C); 26.8; 26.7 (3C); 25.7; 24.3 
(2C); 23.9; 17.7; 16.0 (3C); 15.9. ESI-MS: m/z 606.2 [M-1]+. 
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Synthesis of 7b 
 
 
To a solution of 5 (0.100 g, 0.000258 mol) in dry CH2Cl2 (2.5 ml) sebacic 
acid (6b, 0.104 g, 0.000517 mol), EDC.HCl (0.060 g, 0.000310 mol) and 
DMAP (0.022 g, 0.000181 mol) are added and the reaction mixture is 
stirred at room temperature for 24 h. HCl 1M (15 ml) is added and 
extracted with CH2Cl2 (5x5 ml). The organic layers are dried over Na2SO4 
and the solvent is removed under reduced pressure. The crude is 
purified by flash chromatography (AcOEt/Hex 1:3) to obtain 7b as a 
colorless oil (0.051 g, Yield: 35%). 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 5.06-5.13 (m, 5H); 4.02 (t, J = 9.0 
Hz, 2H); 2.25-2.36 (m, 4H); 1.97-2.08 (m, 20H); 1.59-1.84 (m, 22H); 1.30 
(bs, 8H). 13C-NMR (CDCl3, 75 MHz): δ(ppm)= 178.9; 173.9; 135.1; 134.9; 
1337.7; 125.1; 124.3 (4C); 64.0; 39.7 (3C); 35.8; 34.3; 33.8; 29.7; 29.0 
(4C); 28.2 (3C); 26.9; 26.7 (2C); 25.6; 24.9 (2C); 24.6; 17.7; 16.0 (4C). 
ESI-MS: m/z 507.3 [M-1]+. 
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Synthesis of 8a 
 
 
 
To a solution of 7a (0.024 g, 0.000494 mol), in dry CH2Cl2 (2.5 ml) 
EDC.HCl (0.013 g, 0.000659 mol) and DMAP (0.003 g, 0.000231 mol) are 
added. Then paclitaxel (0.020 g, 0.000330 mol) is added and the 
reaction mixture is stirred at room temperature for 22h. HCl 1M (15 ml) 
is added and extracted with CH2Cl2 (5x5 ml). The organic layers are 
dried over Na2SO4 and the solvent is removed under reduced pressure. 
The crude is purified by flash chromatography (AcOEt/Hex from 1:2 to 
1:1) to obtain 8a as a white solid (0.025 g, Yield: 65%). 
 
1H-NMR (CDCl3, 400 MHz): δ(ppm)= 8.17 (d, J = 7.1Hz, 2H); 7.77 (d, J = 
7.1 Hz, 2H); 7.63 (t, J = 7.1 Hz, 1H); 7.51-7.56 (m, 3H); 7.35-7.47 (m, 
10H); 6.93 (d, J = 9.3 Hz, 1H); 6.32 (s, 1H); 6.28 (t, J = 9.0 Hz, 1H); 6.00 
(dd, J = 9.2 Hz, J = 3.1 Hz, 1H); 5.71 (d, J = 7.1 Hz, 1H); 5.53 (d, J = 3.1 Hz, 
1H); 5.32 (s, 2H); 5.10-5.16 (m, 5H); 5.00 (d, J = 7.6 Hz, 1H); 4.50 (dd, J = 
10.9 Hz, J = 6.6 Hz, 1H); 4.34 (d, J = 8.4 Hz, 1H); 4.23 (d, J = 8.4 Hz, 1H); 
4.05 (t, J = 6.7 Hz, 2H); 3.84 (d, J = 7.0 Hz, 2H); 2.51-2.73 (m, 6H); 2.48 (s, 
3H); 2.25 (t, J = 7.2 Hz, 2H); 2.25 (s, 3H); 2.15-2.22 (m, 2H); 1.87-2.13 
(m, 20H); 1.68-1.79 (m, 8H); 1.63 (bs, 18H); 1.26 (s, 3H); 1.16 (bs, 3H). 
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13C-NMR (CDCl3, 100 MHz, detected signals): δ(ppm)= 204.5; 173.6; 
172.6; 171.9; 170.5; 168.7; 167.8; 143.5; 137.7; 135.8; 135.6; 134.4; 
134.3; 133.5; 132.7; 130.9; 129.8; 129.4; 129.2; 127.8; 127.2; 125.8; 
125.0; 124.9; 85.1; 81.7; 79.9; 77.1; 76.3; 75.8; 74.7; 72.8; 72.5; 65.0; 
59.2; 53.4; 46.3; 43.9; 40.4; 38.4; 37.8; 36.5; 36.3; 33.3; 32.7; 29.0; 27.6; 
27.5; 27.4; 26.4; 24.9; 24.6; 23.4; 22.8; 21.5; 18.3; 16.7; 16.6; 15.5. ESI-
MS (C82H107NO17S2): m/z 1465.8 [M+Na]+. [α]D
22= -46.2300 (c = 0.100, 
CHCl3). 
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Synthesis of 8b 
 
 
 
To a solution of 7b (0.017 g, 0.000035 mol), in dry CH2Cl2 (1.5 ml) 
EDC.HCl (0.009 g, 0.000046 mol) and DMAP (0.002 g, 0.000016 mol) are 
added. Then paclitaxel (0.019 g, 0.000023 mol) is added and the 
reaction mixture is stirred at room temperature for 24h. HCl 1M (15 ml) 
is added and extracted with CH2Cl2 (5x5 ml). The organic layers are 
dried over Na2SO4 and the solvent is removed under reduced pressure. 
The crude is purified by flash chromatography (AcOEt/Hex from 1:2 to 
1:1) to obtain 8b as a white solid (0.013 g, Yield: 40%). 
 
1H-NMR (CD3OD, 400 MHz, detected signals): δ(ppm)= 8.14 (d, J = 8.0 
Hz, 2H); 7.83 (d, J = 8.0 Hz, 2H); 7.70 (t, J = 7.2 Hz, 1H); 7.44-7.63 (m, 
10H); 7.29 (t, J = 7.2 Hz, 1H); 6.48 (s, 1H); 6.09 (t, J = 6.8 Hz, 1H); 5.87 (d, 
J = 6.4 Hz, 1H); 5.66 (d, J = 7.2 Hz, 1H); 5.11-5.16 ( m, 5H); 5.02 (d, J = 8.0 
Hz, 1H); 4.37 (dd, J = 11.2 Hz, J = 6.8 Hz, 1H); 4.21 (s, 2H); 4.05 (t, J = 6.8 
Hz, 2H); 3.84 (d, J = 7.2 Hz, 1H); 2.43-2.50 (m, 5H); 2.30 (t, J = 8.0 Hz, 
2H); 2.19 (s, 3H); 1.99-2.15 (m, 16H); 1.95 (s, 2H); 1.72-1.88 (m, 6H); 
1.68 (bs, 6H); 1.63 (bs, 15H); 1.28 (bs, 8H); 1.56 (bs, 6H). 13C-NMR 
(CD3OD, 100 MHz, detected signals): δ(ppm)= 203.8; 174.2; 174.0; 
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170.2; 169.9; 169.1; 166.3; 141.0; 137.0; 134.6; 134.4; 134.2; 133.5; 
133.2; 131.5; 130.6; 130.0; 129.8; 128.7; 128.5; 128.3; 128.2; 127.2; 
124.9; 124.3; 124.2; 124.1; 84.5; 80.9; 77.7; 76.1; 75.4; 74.9; 74.3; 71.5; 
70.9; 63.6; 57.9; 53.9; 46.5; 43.2; 39.4; 39.3; 36.1; 35.5; 35.1; 33.8; 33.2; 
28.7; 28.5; 27.8; 26.6; 26.5; 26.2; 26.1; 25.6; 24.7; 24.5; 21.9; 21.0; 19.4; 
14.8; 14.6; 13.5; 9.0. ESI-MS (C84H111NO17): m/z 1429.9 [M+Na]+. [α]D
22= 
-24.0900 (c = 0.100, CHCl3). 
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Synthesis of 9a 
 
 
 
To a solution of 7a (0.088 g, 0.000145 mol), in dry CH2Cl2 (2 ml) EDC.HCl 
(0.042 g, 0.000219 mol) and DMAP (0.012 g, 0.000098 mol) are added. 
Then podophyllotoxin (0.060 g, 0.000145 mol) is added and the reaction 
mixture is stirred at room temperature for 24h. HCl 1M (10 ml) is added 
and extracted with CH2Cl2 (3x4 ml). The organic layers are dried over 
Na2SO4 and the solvent is removed under reduced pressure. The crude is 
purified by flash chromatography (CH2Cl2/MeOH 20:1) to obtain 9a as a 
white solid (0.069 g, Yield: 48%). 
 
1H-NMR (CDCl3, 400 MHz): δ(ppm)= 6.79 (s, 1H); 6.57 (s, 1H); 6.42 (bs, 
2H); 6.02 (d, J = 1.0 Hz, 1H); 6.00 (d, J = 1.0 Hz, 1H); 5.92 (dd, J = 9.0 Hz, J 
= 4.0 Hz, 1H); 5.10-5.17 (m, 5H); 4.63 (d, J = 4.2 Hz, 1H); 4.37-4.42 (m, 
1H); 4.19-4.25 (m, 1H); 4.07 (t, J = 6.7 Hz, 2H); 3.83 (s, 3H); 3.79 (s, 6); 
2.83-2.98 (m, 2H); 2.73-2.80 (m, 4H); 2.55-2.64 (m, 2H); 2.46 (t, J = 6.8 
Hz, 2H); 1.95-2.28 (m, 20H); 1.74-1.80 (m, 4H); 1.70 (s, 3H); 1.65 (s, 
15H). 13C-NMR (CDCl3, 100 MHz): δ(ppm)= 125.2; 124.3 (2C); 109.8; 
108.3 (2C); 107.00; 101.6; 73.8; 71.3; 64.3; 60.7; 56.2; 45.6; 43.8; 39.7 
(2C); 38.7; 37.8; 37.7; 35.8; 33.1; 32.6 (2C); 28.3; 26.7; 26.0; 25.2; 24.5 
(2C); 24.3; 24.1 (2C); 16.0 (5C). ESI-MS (C57H78O11S2): m/z 1025.6 
[M+Na]+. [α]D
22= -51.607 (c = 0.100, CHCl3). 
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Synthesis of 9b 
 
 
 
To a solution of 7b (0.055 g, 0.000097 mol), in dry CH2Cl2 (1.5 ml) 
EDC.HCl (0.037 g, 0.000194 mol) and DMAP (0.008 g, 0.000068 mol) are 
added. Then podophyllotoxin (0.040 g, 0.000097 mol) is added and the 
reaction mixture is stirred at room temperature for 18h. HCl 1M (10 ml) 
is added and extracted with CH2Cl2 (3x4 ml). The organic layers are 
dried over Na2SO4 and the solvent is removed under reduced pressure. 
The crude is purified by flash chromatography (AcOEt/Hex 1:2) to 
obtain 9b as a white solid (0.029 g, Yield: 31%). 
 
1H-NMR (CDCl3, 400 MHz): δ(ppm)= 6.77 (s, 1H); 6.57 (s, 1H); 6.42 (s, 
2H); 6.01 (d, J = 6.5 Hz, 2H); 5.91 (d, J = 9.0 Hz, 1H); 5.11-5.21 (m, 5H); 
4.63 (d, J = 4.1 Hz, 1H); 4.39 (t, J = 7.8 Hz, 1H); 4.23 (t, J = 7.8 Hz, 1H); 
4.06 (t, J = 6.7 Hz, 2H); 3.84 (s, 3H); 3.77 (s, 6H); 2.96 (dd, J = 9.0 Hz, J = 
4.5 Hz, 1H); 2.79-2.90 (m, 1H); 2.30-2.47 (m, 16H); 1.52-1.78 (m, 24H); 
1.35 (bs, 8H). 13C-NMR (CDCl3, 100 MHz, detected signals): δ(ppm)= 
152.7; 134.99; 134.87; 132.36; 131.85; 128.46; 125.09; 124.41 (2C); 
124.29 (2C); 109.75; 108.20 (2C); 106.99; 101.60 (2C); 73.44 (2C); 
71.40; 64.02; 60.77; 56.19 (2C); 45.64; 43.79; 39.75 (3C); 38.79; 35.81; 
34.36 (2C); 29.71; 29.11 (4C); 28.28 (3C); 26.95; 26.69 (2C); 24.97 (3C).  
ESI-MS (C59H82O11): m/z 990.6 [M+Na]+. [α]D
22= -53.0800  (c = 0.100, 
CHCl3).  
169 
Synthesis of 10a 
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To a solution of 7a (0.024 g, 0.000494 mol), in dry CH2Cl2 (2.5 ml) 
EDC.HCl (0.013 g, 0.000659 mol) and DMAP (0.003 g, 0.000231 mol) are 
added. Then epothilone (0.020 g, 0.000330 mol) is added and the 
reaction mixture is stirred at room temperature for 48h. HCl 1M (15 ml) 
is added and extracted with CH2Cl2 (5x5 ml). The organic layers are 
dried over Na2SO4 and the solvent is removed under reduced pressure. 
The crude is purified by flash chromatography (AcOEt/Hex from 1:2 to 
1:1) to obtain 10a as a white solid (0.025 g, Yield: 31%). 
 
1H-NMR (CDCl3, 400 MHz): δ(ppm)= 7.05 (s, 1H); 6.73 (s, 1H); 5.71 (dd, 
J = 11.4 Hz, J = 2.4 Hz, 1H); 5.55 (d, J = 7.9 Hz, 1H); 5.46 (d, J = 6.2 Hz, 
1H); 5.37 (d, J = 7.1 Hz, 1H); 5.10-5.17 (m, 5H); 4.15-4.21 (m, 1H); 4.07 
(t, J = 6.7 Hz, 2H); 3.28-3.44 (m, 1H); 3.00-3.11 (m, 1H); 2.89-2.97 (m, 
1H); 2.65-2.82 (m, 8H); 2.38-2.64 (m, 6H); 1.98-2.18 (m, 20H); 1.80-1.95 
(m, 2H); 1.71-1.78 (m, 4H); 1.70 (s, 3H); 1.49-1.68 (m, 21H); 1.41 (s, 
3H); 0.90-1.33 (m, 9H). 13C-NMR (CDCl3, 100 MHz, detected signals): 
δ(ppm)= 216.4; 172.9; 172.5; 170.6; 135.1; 135.0; 133.6; 125.2; 124.4; 
75.8; 71.2; 64.3; 57.6; 57.3; 54.9; 54.4; 43.3; 42.5; 39.7; 38.5; 37.9; 37.6; 
36.1; 35.8; 34.6; 32.7; 30.9; 29.7; 28.3; 26.9; 26.7; 25.7; 24.3; 23.9; 16.9; 
16.0; 15.5. APCI-MS (C61H95NO9S3): m/z 1082.6 [M]+. [α]D
22= -7.5200 (c 
= 0.100, CHCl3).  
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Synthesis of 10b 
 
 
 
To a solution of 7b (0.020 g, 0.000035 mol), in dry CH2Cl2 (2 ml) 
EDC.HCl (0.013 g, 0.000070 mol) and DMAP (0.003 g, 0.000025 mol) are 
added. Then epothilone (0.026 g, 0.0000525 mol) is added and the 
reaction mixture is stirred at room temperature for 96h. HCl 1M (10 ml) 
is added and extracted with CH2Cl2 (4x3 ml). The organic layers are 
dried over Na2SO4 and the solvent is removed under reduced pressure. 
The crude is purified by flash chromatography (AcOEt/Hex 2:3) to 
obtain 10b as a white solid (0.007 g, Yield: 19%). 
 
1H-NMR (CDCl3, 400 MHz, detected signals): δ(ppm)= 7.05 (s, 1H); 6.75 
(s, 1H); 5.72 (dd, J = 11.4 Hz, J = 2.5 Hz, 1H); 5.56 (dd, J = 9.9 Hz, J = 2.2 
Hz, 1H); 5.44 (m, 1H); 5.36 (d, J = 7.4 Hz, 1H); 5.10-5.14 (m, 5H); 4.20 
(m, 1H); 4.05 (t, J = 6.7 Hz, 2H); 3.34-3.40 (m, 1H); 3.05-3.09 (m, 1H); 
2.90-2.94 (m, 1H); 2.82 (m, 2H); 2.50-2.72 (m, 5H); 2.28-2.38 (m, 6H); 
2.97-3.18 (m, 20H); 1.55-1.80 (m, 20H); 0.98-1.47 (m, 26H). 13C-NMR 
(CDCl3, 100 MHz, detected signals): δ(ppm)= 173.9; 173.4; 170.6; 135.1; 
135.0; 133.7; 125.1; 124.4; 75.8; 70.8; 64.0; 57.7; 54.9; 43.6; 39.8; 38.8; 
37.5; 36.1; 35.8; 34.4; 31.6; 29.7; 29.1; 28.3; 26.9; 26.7; 25.7; 25.1; 25.0; 
24.0; 22.7; 17.5; 16.1; 15.9; 15.6. ESI-MS (C63H99NO9S): m/z 1069.4 
[M+Na]+. [α]D
20= -20.1800 (c = 0.100, CHCl3).  
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Synthesis of 11a 
 
 
To a solution of 7a (0.023 g, 0.000038 mol), in dry CH2Cl2 (1.5 ml) 
EDC.HCl (0.015 g, 0.000076 mol) and DMAP (0.003 g, 0.000027 mol) are 
added. Then camptothecin (0.020 g, 0.000057 mol) is added and the 
reaction mixture is stirred at room temperature for 72h. HCl 1M (10 ml) 
is added and extracted with CH2Cl2 (3x4 ml). The organic layers are 
dried over Na2SO4 and the solvent is removed under reduced pressure. 
The crude is purified by flash chromatography (AcOEt 100%) to obtain 
11a as a yellow solid (0.012 g, Yield: 32%). 
1H-NMR (CDCl3, 400 MHz): δ(ppm)= 8.42 (s, 1H); 8.25 (d, J = 8.0 Hz, 
1H); 7.96 (d, J = 8.0 Hz, 1H); 7.86 (t, J = 8.0 Hz, 1H); 7.70 (t, J = 8.0 Hz, 
1H); 7.24 (s, 1H); 5.70 (d, J = 17.2 Hz, 1H); 5.42 (d, J = 17.2 Hz, 1H); 5.31 
(bs, 2H); 5.10-5.16 (m, 5H); 4.04 (t, J = 6.8 Hz, 2H); 2.61-2.76 (m, 6H); 
2.40 (t, J = 7.3 Hz, 2H); 2.28- 2.33 (m, 1H); 2.15-2.20 (m, 1H); 1.98-2.09 
(m, 22H); 1.62-1.76 (m, 20H); 1.00 (t, J = 7.5 Hz, 3H). 13C-NMR (CDCl3, 
100 MHz): δ(ppm)= 173.6; 172.6; 168.2; 158.0; 153.0; 149.6; 147.0; 
146.6; 135.8; 135.7; 134.3; 131.9; 131.4; 130.3; 129.2; 128.9; 128.7; 
125.8; 125.0 (4C); 120.9; 96.6; 67.8; 64.9; 50.6; 40.4 (2C); 38.4; 37.9; 
36.5; 33.3; 32.8; 32.5; 28.9 (2C); 27.6; 27.5 (2C); 26.4; 24.9; 24.6; 18.37; 
16.7 (3C); 16.6; 8.3. ESI-MS (C55H72N2O7S2): m/z 960.3 [M+Na]+. [α]D
20= -
36.3200 (c = 0.100, CHCl3). 
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Synthesis of 11b 
 
 
 
To a solution of 7b (0.030 g, 0.000053 mol), in dry CH2Cl2 (1.5 ml) 
EDC.HCl (0.020 g, 0.000105 mol) and DMAP (0.004 g, 0.000037 mol) are 
added. Then camptothecin (0.027 g, 0.000079 mol) is added and the 
reaction mixture is stirred at room temperature for 48h. HCl 1M (10 ml) 
is added and extracted with CH2Cl2 (4x3 ml). The organic layers are 
dried over Na2SO4 and the solvent is removed under reduced pressure. 
The crude is purified by flash chromatography (AcOEt/Hex 1:1) to 
obtain 11b as a yellow solid (0.013 g, Yield: 28%). 
 
1H-NMR (CDCl3, 400 MHz): δ(ppm)= 8.42 (s, 1H); 8.24 (d, J = 8.0 Hz, 
1H); 7.97 (d, J = 8.0 Hz, 1H); 7.86 (t, J = 8.0 Hz, 1H); 7.69 (t, J = 8.0 Hz, 
1H); 7.24 (s, 1H); 5.70 (d, 16.0 Hz, 1H); 5.42 (d, J = 16.0 Hz, 1H); 5.31 (bs, 
2H); 5.12-5.18 (m, 5H); 4.04(t, J = 7.5 Hz, 2H); 2.48-2.59 (m, 2H); 2.27-
2.36 (m, 1H); 2.21-2.25 (m, 2H); 2.14-2.20 (m, 1H); 1.95-2.14 (m, 20H); 
1.59-1.77 (m, 22H); 1.28 (bs, 8H); 1.00 (t, J = 8.1 Hz, 3H). 13C-NMR 
(CDCl3, 100 MHz, detected signals): δ(ppm)= 167.5; 146.0; 131.2; 130.6; 
129.6; 128.5; 128.2; 128.0; 125.0; 124.4; 124.3; 120.4; 96.0; 67.1; 64.0; 
49.9; 39.7; 35.8; 34.3; 33.8; 31.9; 29.7; 29.1; 29.0; 28.3; 26.9; 26.7; 25.7; 
24.9; 24.6; 16.0; 7.6. ESI-MS (C57H76N2O7): m/z 924.2 [M+Na]+. [α]D
20= -
21.30 00 (c = 0.175, CHCl3). 
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Synthesis of 12 
 
 
 
To a solution of cyclopamine (0.045 g, 0.000109 mol) in dry CH2Cl2 (2 
ml) Fmoc-OSu (0.044 g, 0.000131 mol) is added and the reaction 
mixture is stirred at room temperature for 60 h. The solvent is then 
removed under reduced pressure and the crude material is purified by 
flash chromatography (CH2Cl2/MeOH 10:0.05) to obtain 12 as a white 
solid (0.062 g, Yield: 92%). 
 
1H-NMR: (CDCl3, 300 MHz): δ(ppm)= 7.72 (dd, J= 7.2, 7.2 Hz, 2H); 7.58 
(dd, J = 7.2, 2 Hz, 2H); 7.37 (dd, J= 16, 7.2 Hz, 2H); 7.30(ddd, J=14.8, 7.2, 
1.2 Hz, 2H); 5.37(br d, J= 2.8 Hz, 1H); 4.68 (dd, J= 10.8, 5.2 Hz, 1H); 
4.57(dd, J= 10.8, 5.6 Hz, 1H); 4.21 (dd, J= 5.2, 5.6 Hz, 1H); 3.54 (dd, 
J=12.8, 4.0 Hz, 2H); 3.44 (ddd, J= 11.6, 11.6, 4.0 Hz, 1H); 2.95 (dd, J= 9.6, 
7.2 Hz, 1H); 2.75 (dd, J= 12.8, 8.4 Hz, 1H); 2.39-2.35 (m, 1H); 2.30-2.09 
(m,5H), 1.75 (s, 3H); 1.85-1.63 (m, 5H); 1.59-1.49 (m, 1H), 1.46-1.39 (m, 
4H); 1.35-1.27(m, 1H); 1.23 (ddd, J= 13.2, 3.2, 3.2 Hz, 1H); 1.02-0.88 (m, 
2H); 0.93 (d, J= 6.8 Hz, 3H); 0.93 ( s, 3H); 0.6 (s,3H). 13C-NMR: (CDCl3, 
100 MHz): δ(ppm)= 157.94; 143.97; 143.87; 142.59; 141.69; 141.45; 
141.39; 127.65; 127.62; 127.09; 127.06; 126.66; 124.58; 121.79; 119.99; 
119.95; 84.76; 72.63; 71.73; 66.58; 52.05; 51.05; 49.19; 47.31; 41.78; 
41.57; 41.50; 38.21; 36.56; 35.22; 32.63; 31.35; 31.08; 30.89; 29.00; 
28.28; 24.60; 20.26; 18.66; 13.63; 10.23. ESI-MS: m/z 634.67 [M+ H]+. 
[α]D
= -7.5462 (c = 0.067, CHCl3). 
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Synthesis of 13a 
 
 
 
To a solution of 12 (0.030 g, 0.000047 mol) in CH2Cl2 (1 ml) 7a (0.029 g, 
0.000047 mol), EDC.HCl (0.011 g, 0.000057 mol) and DMAP (0.005 g, 
0.000040 mol) are added and the reaction mixture is stirred at room 
temperature for 24 h. The solvent is then removed under reduced 
pressure and the crude material is purified by flash chromatography 
(CH2Cl2/Hex 8:2) to obtain 13a as a colorless oil (0.030 g, Yield: 52%). 
 
1H-NMR: (CDCl3, 300 MHz): δ(ppm)= 7.68-7.80 (m, 2H); 7.51-7.60 (m, 
2H); 7.22-7.41 (m, 4H); 5.35-5.45 (m, 1H); 5.06-5.20 (m, 5H); 4.50-4.74 
(m, 2H); 4.00-4.25 (m, 4H); 3.27-3.70 (m, 2H); 2.92-2.97 (m, 1H); 2.69-
2.80 (m, 4H); 2.40-2.45 (m, 4H); 0.91-2.38 (m, 74H). ESI-MS: m/z 
1246.1 [M+Na]+. [α]D
	 = -4.9062 (c = 0.133, CHCl3). 
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Synthesis of 13b 
 
 
 
To a solution of 12 (0.031 g, 0.000049 mol) in CH2Cl2 (1 ml) 7b (0.028 g, 
0.000049 mol), EDC.HCl (0.011 g, 0.000058 mol) and DMAP (0.005 g, 
0.000041 mol) are added and the reaction mixture is stirred at room 
temperature for 24 h. The solvent is then removed under reduced 
pressure and the crude material is purified by flash chromatography 
(CH2Cl2/Hex 13:7) to obtain 13b as a colorless oil (0.027 g, Yield: 47%). 
1H-NMR: (CDCl3, 300 MHz): δ(ppm)= 7.65-2.80 (m, 2H); 7.50-2.75 (m, 
2H); 7.13-7.50 (m, 4H); 5.31-5.45 (m, 1H); 5.00-5.20 (m, 5H); 4.50 - 4.70 
(m, 2H); 4.13-4.25 (m, 1H); 3.92-4.10 (m, 3H); 2.75-3.30 (m, 2H); 2.69-
2.80 (m, 1H);0.67-2.45 (m, 88H). ESI-MS: m/z 1209.3 [M+Na]+. [α]D
	 = -
5.5589 (c = 0.133, CHCl3). 
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Synthesis of 14a 
 
 
 
To a solution of 13a (0.030 g, 0.000024 mol) in CH2Cl2 (0.6 ml) 
diethylamine (0.106 g, 0.001447 mol) was added and the reaction 
mixture was stirred at room temperature for 72 h. The volatiles were 
then removed under reduced pressure and the crude material was 
purified by flash chromatography ( from 100% CH2Cl2 to AcOEt/MeOH 
25:1) to obtain 14a as a colorless oil (0.013 g, Yield: 52%). 
 
1H-NMR: (CDCl3, 300 MHz): δ(ppm)= 5.40 (m, 1H); 5.03-5.20 (m, 5H); 
4.56-4.70 (m, 2H); 4.03 (t, J= 7.1Hz, 2H); 3.32-3.51 (m, 2H); 3.14-3.25 
(m, 1H); 2.71 (t, J=7.1 Hz, 4H); 2.37-2.46 (m, 4H); 0.81-2.32 (m, 76H). 
13C-NMR: (CDCl3, 75 MHz, detected signals): δ(ppm)= 172.94; 172.27; 
144.25; 142.67; 140.42; 135.10; 134.45; 133.60; 126.95; 125.19; 125.12; 
124.38; 124.36; 134.20; 122.78; 86.32; 84.67; 73.92; 69.82; 64.62; 
64.30; 51.85; 49.05; 41.51; 39.72; 39.64; 39.59; 39.57; 38.22; 37.84; 
37.63; 36.60; 35.76; 33.68; 32.96; 31.03; 29.67; 29.14; 28.90; 28.39; 
28.24; 27.51; 26.84; 26.75; 26.64; 26.57; 24.29; 24.21; 24.16; 19.30; 
18.55; 18.42; 17.65; 16.02; 15.85; 13.69; 13.09; 10.72. ESI-MS: m/z 
1000.9 [M+1]+. [α]D
	 = -12.0955 (c = 0.660, CHCl3). 
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Synthesis of 14b 
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To a solution of 13b (0.027 g, 0.000023 mol) in CH2Cl2 (0.6 ml) 
diethylamine (0.098 g, 0.001342 mol) was added and the reaction 
mixture was stirred at room temperature for 72 h. The volatiles were 
then removed under reduced pressure and the crude material was 
purified by flash chromatography ( from 100% CH2Cl2 to AcOEt/MeOH 
25:1) to obtain 14b as a colorless oil (0.007 g, Yield: 29%). 
 
1H-NMR: (CDCl3, 300 MHz): δ(ppm)= 5.38-5.42 (m, 1H); 5.00- 5.20 (m, 
5H); 4.50-4.70 (m, 2H); 4.02 (t, J= 6.4Hz, 2H); 3.25-3.40 (m, 1H); 3.11-
3.19 (m, 1H); 2.68-2.79 (m, 1H); 2.48-2.62 (m, 1H); 0.80-2.45 (m, 87H). 
13C-NMR: (CDCl3, 75 MHz, detected signals): δ(ppm)= 173.87; 173.20; 
144.29; 140.51; 134.96; 133.67; 125.04; 124.37; 124.25; 122.66; 86.34; 
73.54; 63.95; 51.86; 49.05; 39.71; 39.64; 35.77; 34.33; 29.06; 28.24; 
26.89; 26.63; 24.96; 18.56; 18.41; 17.65; 16.00; 15.83; 13.08. ESI-MS: 
m/z 965.0 [M+1]+. [α]D
	 = -17.9880 (c = 0.467, CHCl3). 
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Synthesis of 16 
 
 
 
H-Lys(Z)-OH (15, 0.500 g, 0.001786 mol) is suspended in MeOH (17 ml). 
At 0°C, SOCl2 (0.257 ml, 0.003571 mol) is added dropwise and the 
reaction mixture is stirred overnight at room temperature. The volatiles 
are then removed under reduced pressure, affording 16 as a white solid 
without any further purification (0.580 g, Yield: 99%). 
 
1H-NMR (CDCl3, 300 MHz): δ (ppm)= 8.69 (bs, 3H); 7.31 (bs, 5H); 5.50 
(bs, 1H); 5.05 (s, 2H); 4.10 (bs, 1H); 3.74 (s, 3H); 3.16 (bs, 2H); 2.51 (bs, 
2H); 2.02 (bs, 2H); 1.51 (bs, 2H). 13C-NMR (CDCl3, 75 MHz): δ (ppm)= 
169.9; 156.7; 136.7; 128.5 (2C); 128.0 (2C); 127.9; 65.5; 53.3; 53.0; 40.3; 
29.7; 28.9; 21.9. [α]D
22: +11.676 (c=0.800, CHCl3). 
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Synthesis of 18 
 
 
 
To a solution of 16 (1.178 g, 0.003570 mol) in CH2Cl2 (35 ml) DMAP 
(0.740 g, 0.006068 mol) is added. Boc-Phe-OH (17, 0.946 g, 0.003570 
mol) and EDC.HCl (1.028 g, 0.005355 mol) are then added and the 
reaction mixture is stirred overnight at room temperature.  
The solvent is then removed under reduced pressure and the crude  
residue is purified by flash chromatography (AcOEt:Hex from 1:2 to 2:1) 
affording 18 as a white solid (1.196 g, Yield: 62%). 
 
1H-NMR (CD3OD, 300 MHz): δ (ppm)= 7.13-7.33 (m, 10H); 6.69 (bs, 1H); 
5.03-5.22 (m, 4H); 4.48-4.55 (m, 1H); 3.67 (s, 3H); 2.90-3.18 (m, 4H); 
1.45-1.86 (m, 4H); 1.37 (s, 9H); 1.06-1.30 (m, 2H). 13C-NMR (CD3OD, 75 
MHz): δ (ppm)= 172.2; 171.2; 156.5; 155.5; 136.6 (2C); 129.3 (3C); 
128.6 (4C); 128.1 (2C); 126.9; 80.2; 66.7; 57.8; 52.4; 51.9; 40.5; 38.1; 
31.9; 29.2; 28.3; 22.1. [α]D
33: -14.636 (c=0.450, CH3OH). 
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Synthesis of 19 
 
 
 
To a solution of 18 (0.127 g, 0.000234 mol) in CH2Cl2 (2 ml) TFA (1.5 
ml) is added and the reaction mixture is stirred at room temperature for 
1h. The volatiles are then removed under reduced pressure, affording 
19 as a white solid without any further purification (0.130 g, Yield: 
99%). 
 
1H-NMR (CD3OD, 300 MHz): δ (ppm)= 8.20 (bs, 3H); 7.67 (bs, 1H); 7.11-
7.42 (m, 10H); 5.15 (bs, 1H); 4.99 (s, 2H); 4.40 (bs, 1H); 4.29 (bs, 1H); 
3.61 (s, 3H); 2.95-3.30 (m, 4H); 1.12-1.86 (m, 6H). 13C-NMR (CD3OD, 75 
MHz): δ (ppm)= 173.7; 170.0; 159.3; 138.7; 135.8; 130.9 (2C); 130.4 
(2C); 129.8; 129.2 (5H); 67.7; 55.8; 54.2; 53.1; 41.8; 38.8; 32.4; 30.7; 
24.2. ESI-MS: 442 [M-TFA+1]+. [α]D
33: +0.958 (c=1.050, CH3OH). 
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Synthesis of 21 
 
 
 
To a solution of 19 (0.525 g, 0.000946 mol) in CH2Cl2 (9 ml) DMAP 
(0.231 g, 0.001892 mol) is added. Boc-D-Ala-OH (20, 0.179 g, 0.000946 
mol) and EDC.HCl (0.272 g, 0.001419 mol) are then added and the 
reaction mixture is stirred overnight at room temperature. The solvent 
is then removed under reduced pressure and the crude  residue is 
purified by flash chromatography (AcOEt:Hex 1:2) affording 21 as a 
white solid (0.496 g, Yield: 85%). 
 
1H-NMR (CD3OD, 300 MHz): δ (ppm)= 7.16-7.39 (m, 10H); 6.59-6.62 (m, 
2H); 5.04-5.29 (m, 4H); 4.46-4.63 (m, 3H); 3.68 (s, 3H); 3.02-3.23 (m, 
4H); 0.97-1.84 (m, 18H). 13C-NMR (CD3OD, 75 MHz): δ (ppm)= 173.1; 
172.2; 170.7; 156.6; 155.7; 136.6 (2C); 129.3 (2C); 128.6 (3C); 128.1 
(3C); 126.9; 80.2; 66.7; 54.3; 52.3; 52.0; 50.1; 40.4; 37.3; 31.2; 29.0; 28.3 
(3C); 22.2; 17.9. ESI-MS: 636 [M+Na]+. [α]D
22: -9.115 (c=1.000, CH3OH). 
  
182   
Synthesis of 22 
 
 
 
To a solution of 21 (1.125 g, 0.001835 mol) in dry MeOH (28 ml) Pd/C 
10% (0.195 g, 0.000183 mol) is added and the reaction mixture is 
stirred under H2 pressure at room temperature for 3 hours. After 
filtration over celite and evaporation of the solvent under reduced 
pressure, the desired 22 is obtained as a white solid without any further 
purification (0.866 g, Yield: 98%). 
 
1H-NMR (CD3OD, 300 MHz): δ (ppm)= 7.18-7.32 (m, 5H); 4.62-4.66 (m, 
1H); 4.37-4.48 (m, 1H); 3.90-3.97 (m, 1H); 3.68 (s, 3H); 3.30 (bs, 2H); 
2.88 (dd, J = 13.9 Hz, J = 9.8 Hz, 1H); 2.66 (t, J = 6.5 Hz, 2H); 1.76-1.88 (m, 
2H); 1.48-1.50 (m, 2H); 1.41 (s, 9H); 1.06 (d, J = 7.0 Hz, 3H). 13C-NMR 
(CD3OD, 75 MHz): δ (ppm)= 176.2; 174.0; 173.9 (2C); 138.8; 130.6 (2C); 
129.7 (2C); 128.0; 80.9;55.8; 54.0; 53.0; 52.2; 42.4; 38.6;32.3; 31.6; 29.0 
(3C); 24.3; 18.2. ESI-MS: 479 [M +1]+. [α]D
22: -8.646 (c=1.000, CH3OH). 
  
183 
Synthesis of 23 
 
 
 
To a solution of 22 (1.853 g, 0.003868 mol) in THF (35 ml) NaOH 5% 
(10 ml) and Boc2O (1.265 g, 0.005803 mol) are added and the reaction 
mixture is stirred overnight at room temperature. The solvent is 
removed under reduced pressure, H2O (40 ml) is added and the pH 
value is adjusted to 5 with HCl 0.1M. The precipitate is recovered by 
filtration and washed with H2O, obtaining the desired product 23 
without any further purification (1.831 g, Yield: 84%). 
 
1H-NMR (CD3OD, 300 MHz): δ (ppm)= 7.19-7.30 (m, 5H); 4.66-4.70 (m, 
1H); 4.38 (dd, J = 9.0 Hz, J = 4.9 Hz, 1H); 3.99 (q, J = 7.2 Hz, 1H); 3.27-
3.31 (m, 1H); 3.06 (t, J = 6.3 Hz, 2H); 2.92 (dd, J = 14.0 Hz, J = 9.8 Hz, 1H); 
1.89-1.94 (m, 1H); 1.79-1.84 (m, 1H); 1.42-1.56 (m, 22H); 1.10 (d, J = 7.2 
Hz). 13C-NMR (CD3OD, 75 MHz): δ (ppm)= 174.4; 173.8; 172.0; 157.1; 
156.2; 137.1; 129.0 (2C); 128.0 (2C); 126.3; 79.3; 78.5; 54.0; 52.5; 50.4; 
39.8; 36.9; 30.9; 29.1; 27.4 (6C); 22.8; 16.6. ESI-MS: 563 [M- 1]+. [α]D
22: -
1.168 (c=1.000, CH3OH). 
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Synthesis of 25 
 
 
 
A solution of Cbz-Cl (1.000 g, 0.005848 mol) in CH2Cl2 (90 ml) is added 
dropwise over 1.5 hours to a solution of ethylenediamine (24, 2.342 ml, 
0.035088 mol) in CH2Cl2 (10 ml) and stirred at room temperature for 1 
h. Then the solvent is removed under reduced pressure, a saturated 
solution of K2CO3 (140 ml) is added and extracted with AcOEt (3x30 ml). 
The organic layers are dried over Na2SO4 and evaporated under reduced 
pressure, affording 25 as a pale yellow oil without any further 
purification (1.049 g, Yield: 92%). 
1H-NMR (CDCl3, 300 MHz): δ (ppm)= 7.29-7.32 (m, 5H); 5.31 (bs, 1H); 
5.08 (s, 2H); 3.18-3.23 (m, 2H); 2.76-2.80 (m, 2H); 1.32 (bs, 2H). 13C-
NMR (CDCl3, 75 MHz): δ (ppm)= 156.7; 136.6; 128.6; 128.2; 66.8; 43.8; 
41.8. 
  
185 
Synthesis of 26 
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To a solution of 23 (0.900 g, 0.001593 mol) in CH2Cl2 (15 ml) EDC.HCl 
(0.459 g, 0.002389 mol), DMAP (0.136 g, 0.001115 mol) and finally 25 
(0.309 g, 0.001593 mol) are added and the reaction mixture is stirred 
overnight at room temperature. Then the solvent is removed under 
reduced pressure and the crude material is purified by flash 
chromatography (AcOEt 100%), affording 26 as a white solid (0.430 g, 
Yield: 36%).  
1H-NMR (CD3OD, 300 MHz): δ (ppm)= 7.13-7.34 (m, 10H); 5.07 (s, 2H); 
4.53-4.58 (m, 1H); 4.19-4.24 (m, 1H); 3.94 (q, J = 9.1 Hz, 1H); 3.17-3.25 
(m, 4H); 3.02 (t, J = 6.2 Hz, 2H); 2.90 (dd, J = 14.2 Hz, J = 10.1 Hz, 1H); 
1.62-1.97 (m, 2H); 1.28-1.56 (m, 22H); 1.07 (d, J = 7.0 Hz, 3H). 13C-NMR 
(CD3OD, 75 MHz): δ (ppm)= 177.1; 174.7; 174.0; 159.2; 158.9; 158.3; 
138.8 (2C); 130.5 (3C); 129.8 (3C); 129.3 (2C); 128.1; 81.0 (2C); 67.8; 
56.6; 55.6; 52.1; 41.5 (2C); 40.9; 38.1; 32.4; 30.8; 29.1 (6C); 24.8; 17.9. 
ESI-MS: 764 [M+Na]+. [α]D
33: +8.3265 (c=0.8300, CH3OH). 
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Synthesis of 27 
 
 
 
To a solution of 26 (0.067 g, 0.000090 mol) in dry MeOH (1.5 ml) Pd/C 
10% (0.010 g, 0.000009 mol) is added and the reaction mixture is 
stirred under H2 pressure at room temperature for 4 hours. After 
filtration over celite and evaporation of the solvent under reduced 
pressure, the desired 27 is obtained as a white solid without any further 
purification (0.053 g, Yield: 97%). 
 
1H-NMR (CD3OD, 400 MHz): δ (ppm)= 7.22-7.33 (m, 5H); 4.55-4.57 (m, 
1H); 4.24 (dd, J = 9.7 Hz, J = 4.7 Hz, 1H); 3.98 (q, J = 7.1 Hz, 1H); 3.20-
3.30 (m, 3H); 3.05 (t, J = 6.7 Hz, 2H); 2.95 (dd, J = 14.2 Hz, J = 9.8 Hz, 1H); 
2.75 (t, J = 6.1 Hz, 2H); 1.91 (bs, 1H); 1.78 (bs, 1H); 1.45 (bs, 13H); 1.42 
(s, 9H); 1.13 (d, J = 7.1 Hz, 3H). 13C-NMR (CD3OD, 100 MHz): δ (ppm)= 
176.2; 173.8; 173.0; 157.8; 157.2; 137.7 (2C); 129.5 (2C); 128.8 (2C); 
127.1; 80.0; 79.1; 55.7; 54.7; 51.1; 42.4; 41.0; 40.4; 37.0; 31.3; 29.8; 28.1 
(6C); 23.9; 16.8. ESI-MS: 630 [M+Na]+. [α]D
33: +0.6926 (c=0.6050, 
CH3OH). 
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Synthesis of 28 
 
N
H
Boc
H
N
O
N
H
O
H
N
O
NH2
HN
Boc
Ph
4
mol.sieves
dry MeOH
0°C rt
overnight
N
H
Boc
H
N
O
N
H
O
H
N
O
N
H
HN
Boc
Ph
Sq
NaBH(OAc)3
SqH
O
27
28  
 
27 (0.236 g, 0.000390 mol) and 4Å molecular sieves are added at 0 °C to 
a solution of 4 (0.060 g, 0.000156 mol) in dry MeOH (2 ml). The reaction 
mixture is stirred for 1 h, NaBH(OAc)3 (0.046 g, 0.000218 mol) is added 
and then warmed up to room temperature and stirred overnight. The 
solvent is then evaporated and the crude material is purified by flash 
chromatography (CH2Cl2/MeOH from 10:1 to 7:3), affording 28 as a pale 
yellow solid (0.088 g, Yield: 58%). 
 
1H-NMR (CD3OD, 400 MHz): δ (ppm)= 7.22-7.34 (m, 5H); 5.10-5.24 (m, 
5H); 4.44-4.56 (m, 1H); 4.08-4.20 (m, 1H); 3.97-4.02 (m, 1H); 2.82-3.59 
(m, 10H); 1.96-2.17 (m, 24H); 1.73-1.86 (m, 2H); 1.69 (s, 3H); 1.65 (s, 
3H); 1.61 (bs, 9H); 1.46 (bs, 18H); 1.42 (s, 3H); 1.12 (d, J = 7.1 Hz, 3H). 
13C-NMR (CD3OD, 100 MHz, detected signals): δ (ppm)= 175.1; 173.8; 
173.7; 172.9; 157.1; 137.0; 134.6; 134.5; 133.1; 130.7; 129.0; 128.8; 
128.2; 126.6; 126.5; 125.3; 124.7; 124.2; 124.1; 79.4; 78.5; 55.2; 54.4; 
50.6; 39.5; 36.8; 36.4; 30.4; 29.1; 27.8; 27.4; 26.4; 26.2; 25.1; 23.1; 14.8. 
ESI-MS: m/z 998.2 [M+Na]+. [α]D
31: +9.3570 (c=1.0000, CH3OH). 
188   
Synthesis of 29 
 
 
 
To a solution of paclitaxel (0.060 g, 0.000070 mol) in dry CH2Cl2 (1 ml) 
dry pyridine (0.017 g, 0.000211 mol) and p-nitrophenyl-chloroformate 
(0.028 g, 0.000141 mol) were added and the reaction mixture was 
stirred at room temperature for 18 h. Then the volatiles were removed 
under reduced pressure and the crude material was purified by flash 
chromatography (AcOEt/Hex 4:5) affording 29 as a white solid (0.042 g, 
Yield: 59%). 
 
1H-NMR (CDCl3, 300 MHz): δ (ppm)= 8.24 (d, J = 7.2 Hz, 2H); 8.13 (d, J = 
7.6 Hz, 2H); 7.75 (d, J = 7.6 Hz, 2H); 7.62 (t, J = 7.2 Hz, 1H); 7.39-7.53 (m, 
10H); 7.32 (d, J = 9.2 Hz, 2H); 6.89 (d, J = 9.3 Hz, 1H); 6.37 (bs, 1H); 6.31 
(t, J = 8.9 Hz, 1H); 6.07 (d, J = 9.3 Hz, 1H); 5.72 (d, J = 6.8 Hz, 1H); 5.51-
5.58 (m, 2H); 4.99 (d, J = 8.8 Hz, 1H); 4.36 (d, J = 8.5 Hz, 1H); 4.20 (d, J = 
8.5 Hz, 1H); 3.98 (d, J = 6.8 Hz, 1H); 2.66-2.76 (m, 1H); 2.39-2.48 (m, 
4H); 2.24-2.32 (m, 1H); 2.18 (s, 3H); 1.97-2.09 (m, 4H); 1.86 (s, 3H); 1.24 
(s, 3H); 1.18 (s, 3H). FAB-MS: m/z 1042.2 [M+Na]+.  
189 
Synthesis of 32  
 
 
 
To a solution of 29 (0.035 g, 0.000034 mol) in dry DMF (1.5 ml) 28 
(0.035 g, 0.000068 mol) was added and the reaction mixture was stirred 
at 120°C  for 8 h. The solvent was removed under reduced pressure and 
the crude material was purified by flash chromatography (AcOEt/Hex 
1:1) affording 32 as a white solid (0.014 g, Yield: 22%). 
 
1H-NMR (CDCl3, 400 MHz): δ (ppm)= 8.11 (d, J = 7.0 Hz, 2H); 7.73 (d, J = 
8.1 Hz, 2H); 7.62-7.68 (m, 1H); 7.17-7.48 (m, 10H); 6.89-6.98 (m, 1H); 
6.16-6.45 (m, 4H); 5.70-5.79 (m, 2H); 5.08-5.19 (m, 5H); 4.81-5.02 (m, 
1H); 4.53-4.68 (m, 1H); 3.95-4.37 (m, 4H); 2.54-3.65 (m, 10H); 1.10-2.35 
(m, 93H). ESI-MS: 1854.3 [M-1]+ [α]D
33: -19.4500 (c=0.2000, CH3OH). 
190   
Synthesis of 35  
 
 
 
To a solution of 32 (0.014 g, 0.000007 mol) in CH2Cl2 (1.0 ml) a drop of a 
saturated solution of HCl in MeOH was added and the reaction mixture 
was stirred at room temperature for 10 min. The volatiles were then 
evaporated under reduced pressure affording 35 (0.012 g, Yield: 95%) 
without any further purification. 
1H-NMR (CDCl3, 300 MHz): δ (ppm)= 7.11-8.28 (m, 16 H); 6.23-6.55 (m, 
2H); 5.51-6.03 (m, 4H); 5.09-5.18 (m, 5H); 4.60-4.98 (m, 2H); 4.05-4.52 
(m, 4H); 2.48-3.75 (m, 10H); 0.79-2.48 (m, 75H). ESI-MS: 1773.9 
[M+2Na]++ [α]D
25: -20.4734 (c=0.6400, CH3OH).  
191 
Synthesis of 30[163] 
 
 
 
To a solution of podophyllotoxin (0.100 g, 0.000242 mol) in dry CH2Cl2 
(2 ml) dry pyridine (0.035 g, 0.000430 mol) and p-nitrophenyl-
chloroformate (0.097 g, 0.000483 mol) were added and the reaction 
mixture was stirred at room temperature for 18 h. Then the volatiles 
were removed under reduced pressure and the crude material was 
purified by flash chromatography (AcOEt/Hex 1:1) affording 30 as a 
pale yellow solid (0.105 g, Yield: 75%). 
1H-NMR (CDCl3, 300 MHz): δ (ppm)= 8.32 (d, J = 7.5 Hz, 2H); 7.43 (d, J = 
7.5 Hz, 2H); 6.94 (s, 1H); 6.58 (s, 1H); 6.40 (s, 2H); 6.01 (bs, 2H); 5.88 (d, 
J = 9.0 Hz, 1H); 4.64 (d, J = 6.0 Hz, 1H); 4.51 (dd, J = 8.9 Hz, J = 6.7 Hz, 
1H); 4.25 (t, J = 9.6 Hz, 1H); 3.81 (s, 3H); 3.76 (bs, 6H); 2.92-3.06 (m, 
2H). 13C-NMR (CDCl3, 75 MHz): δ (ppm)= 173.7; 155.2; 152.8; 149.6; 
148.5; 147.6; 145.6; 134.3; 133.4; 126.3; 125.4; 121.6; 110.5; 109.6; 
108.5; 101.9; 74.2; 66.9; 60.7; 56.3; 43.9; 43.8; 41.2; 36.8. FAB-MS: 
580.6 [M+1]+. [α]D
25: -122.1000 (c=1.0000, CHCl3). 
 
  
192   
Synthesis of 33  
 
 
 
To a solution of 30 (0.037 g, 0.000064 mol) in dry DMF (1.2 ml) 28 
(0.062 g, 0.000064 mol) was added and the reaction mixture was stirred 
at 120°C  for 8 h. The solvent was removed under reduced pressure and 
the crude material was purified by flash chromatography (AcOEt/Hex 
1:1) affording 33 as a white solid (0.044 g, Yield: 49%). 
 
1H-NMR (CD3OD, 300 MHz): δ (ppm)= 7.18-7.31 (m, 5H); 6.96 (s, 1H); 
6.52 (s, 1H); 6.41-6.48 (m, 2H); 5.83-5.91 (m, 3H); 5.05-5.19 (m, 5H); 
3.90-4.64 (m, 6H); 3.71 (bs, 9H); 2.83-3.59 (m, 12H); 1.91-2.25 (24H); 
1.55-1.80 (m, 20H); 1.41 (bs, 18H); 1.09 (d, J = 6.9 Hz, 3H). ESI-MS: 
1438.5 [M+Na]+. [α]D
33: -158.0660 (c=0.0667, CH3OH). 
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Synthesis of 36 
 
 
 
To a solution of 33 (0.010 g, 0.000007 mol) in CH2Cl2 (0.5 ml) a drop of a 
saturated solution of HCl in MeOH was added and the reaction mixture 
was stirred at room temperature for 10 min. The volatiles were then 
evaporated under reduced pressure affording 36 (0.008 g, Yield: 90%) 
without any further purification. 
 
1H-NMR (CD3OD, 400 MHz): δ (ppm)= 7.21-7.38 (m, 5H); 6.95 (s, 1H); 
6.56 (s, 1H); 6.47-6.50 (m, 2H); 5.90-5.98 (m, 3H); 5.12-5.25 (m, 5H); 
4.45-4.73 (m, 3H); 4.07-4.38 (m, 2H); 3.83-3.89 (m, 1H); 3.74 (bs, 9H); 
194   
2.81-3.70 (m, 12H); 1.11-2.16 (m, 47H). 13C-NMR (CD3OD, 100 MHz, 
detected signals): δ (ppm)= 148.2; 129.1; 129.0; 128.2; 126.6; 126.5; 
124.3; 124.2; 108.4; 55.3; 39.4; 39.1; 37.1; 36.5; 35.9; 29.3; 27.8; 26.6; 
26.4; 26.3; 26.2; 22.0; 14.8. ESI-MS: 1239.1 [M-2HCl+Na]+. [α]D
25: -
141.0000 (c=0.1000, CH3OH). 
 
  
195 
Synthesis of 31  
 
 
 
To a solution of camptothecin (0.060 g, 0.000172 mol) in dry CH2Cl2 (1.5 
ml) dry pyridine (0.054 g, 0.000690 mol) and p-nitrophenyl-
chloroformate (0.104 g, 0.000517 mol) were added and the reaction 
mixture was stirred at room temperature for 48 h. Then the volatiles 
were removed under reduced pressure and the crude material was 
purified by flash chromatography (CH2Cl2/MeOH 80:1) affording 31 as a 
yellow solid (0.035 g, Yield: 40%). 
 
1H-NMR (CDCl3, 300 MHz): δ (ppm)= 8.42 (s, 1H); 8.15-8.23 (m, 3H); 
7.95 (d, J = 7.6 Hz, 1H); 7.86 (t, J = 7.6 Hz, 1H); 7.68 (t, J = 7.6 Hz, 1H); 
7.36-7.42 (m, 3H); 5.71 (d, J = 17.5 Hz, 1H); 5.40 (d, J = 17.5 Hz, 1H); 5.30 
(bs, 2H); 2.17-2.42 (m, 2H); 1.06 (t, J = 7.6 Hz, 3H). ESI-MS: 536.2 
[M+Na]+. [α]D
25: +20.5700 (c=1.0000, CHCl3). 
  
196   
Synthesis of 34  
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To a solution of 31 (0.035 g, 0.000068 mol) in dry DMF (1.5 ml) 28 
(0.066 g, 0.000068 mol) was added and the reaction mixture was stirred 
at 90°C  for 24 h. The solvent was removed under reduced pressure and 
the crude material was purified by flash chromatography (CH2Cl2/MeOH 
30:1) affording 34 as a yellow solid (0.016 g, Yield: 17%). 
 
1H-NMR (CD3OD, 300 MHz): δ (ppm)= 8.70 (bs, 1H); 8.11-8.20 (m, 1H); 
8.00-8.09 (m, 1H); 7.79-7.90 (m, 1H); 7.62-7.73 (m, 1H); 7.38-7.47 (m, 
1H); 7.11-7.29 (m, 5H); 5.54-5.60 (m, 1H); 5.47-5.51 (m, 1H); 5.30 (bs, 
2H); 5.01-5.19 (m, 5H); 4.49-4.68 (m, 1H); 4.10-4.38 (m, 1H); 3.88-4.00 
(m, 1H); 2.74-3.61 (m, 10H); 1.82-2.29 (m, 26H); 1.21-1.74 (m, 38H); 
1.05-1.12 (m, 6H). ESI-MS: 1372.3 [M+Na]+. [α]D
25: -48.7706 (c=0.0667, 
CH3OH).  
197 
Synthesis of 37  
 
 
 
To a solution of 34 (0.009 g, 0.000007 mol) in CH2Cl2 (0.5 ml) a drop of a 
saturated solution of HCl in MeOH was added and the reaction mixture 
was stirred at room temperature for 10 min. The volatiles were then 
evaporated under reduced pressure affording 37 (0.008 g, Yield: 98%) 
without any further purification. 
 
1H-NMR (CD3OD, 400 MHz): δ (ppm)= 8.38-8.50 (m, 1H); 8.30-8.37 (m, 
1H); 8.18-8.29 (m, 1H); 7.96-8.10 (m, 1H); 7.77-7.93 (m, 2H); 7.08-7.33 
(m, 5H); 5.61-5.70 (m, 1H); 5.48-5.56 (m, 1H); 5.42 (bs, 2H); 5.08-5.21 
(m, 5H); 4.50-4.58 (m, 1H); 4.37-4.48 (m, 1H); 4.19-4.26 (m, 1H); 2.82-
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3.94 (m, 10H); 1.07-2.31 (m, 52H). 13C-NMR (CD3OD, 100 MHz, detected 
signals): δ (ppm)= 136.8; 129.0; 128.7; 128.1; 127.9; 126.5; 76.4; 66.3; 
54.8; 53.5; 50.5; 43.7; 39.1; 37.4; 31.5; 30.9; 29.3; 26.7; 22.6; 22.3; 16.1; 
7.1. ESI-MS: 1223.9 [M+Na]+. [α]D
25: -31.7100 (c=0.1000, CH3OH). 
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Synthesis of 38 
 
 
 
Sodium dichromate dihydrate (6.350 g, 0.021780 mol) was slowly 
added at 0°C to a solution of sulfuric acid (11.600 ml, 0.217796 mol) in 
H2O (110 ml). The resulting solution was then added to a solution of 4 
(7.940 g, 0.021778 mol) in Et2O (160 ml) and stirred at 0 °C for 2 h. The 
reaction mixture was washed with brine (3 x 1000 ml) until neutral pH, 
then dried over Na2SO4 and evaporated under reduced pressure. The 
crude material was purified by flash chromatography (petroleum 
ether/Et2O 95:5) obtaining 38 as a colorless oil (2.862 g, Yield: 35%). 
 
1H-NMR (Acetone-d6, 300 MHz): δ (ppm) = 5.11 (m, 5H), 2.38 (t, J = 7.1 
Hz, 2H), 2.26 (t, J = 7.1 Hz, 2H), 2.13-1.86 (m, 16H), 1.65-1.59 (m, 15H), 
1.26 (s, 3H). EI-MS: m/z 400 [M]+. 
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Synthesis of PTX-Sq (39) 
 
 
To a solution of paclitaxel (1.200 g, 0.001405 mol) in CH2Cl2 (30 ml) 
EDC.HCl (0.270 g, 0.001405 mol), DMAP (0.120 g, 0.000983 mol) and 38 
(0.562 g, 0.001405 mol) were added and the reaction mixture was 
stirred at room temperature for 3 h. The reaction mixture was then 
extracted with HCl 0.1 M (3 x 15 ml), the organic layers were dried over 
Na2SO4 and evaporated under reduced pressure. The crude material 
was then purified by flash chromatography (CH2Cl2/AcOEt from 95:5 to 
80:20) affording PTX-SQ (39) as a white solid (1.128 g, Yield: 65%). 
 
1H NMR (CDCl3, 300 MHz): δ (ppm) = 8.13 (d, J = 7.3 Hz, 2H); 7.75 (d, J = 
6.9 Hz, 2H); 7.62 (t, J = 7.1 Hz, 1H); 7.53-7.49 (m, 3H); 7.43-7.35 (m, 7H); 
6.91 (d,1H); 6.35 (s, 1H); 6.24 (m, 1H); 5.99 (m, 1H); 5.69 (d, 1H); 5.53 
(d, 1H); 5.20 (m, 5H); 4.97 (d, 1H); 4.44 (m, 1H); 4.33 (d, 1H); 4.20 (d, 
1H); 3.85 (d, 1H); 2.55 (m 1H); 2.49 (s, 3H); 2.45 (m, 2H); 2.30 (t, 2H); 
2.23 (s, 3H); 2.09 (s, 3H); 2.00 (m, 16H); 1.97 (m, 1H); 1.70 (m, 1H); 1.67 
(s, 3H); 1.61 (m, 18H); 1,25 (m, 1H); 1.21 (s, 3H); 1.13 (s, 3H). ESI-MS: 
m/z 1237.2 [M+H]+.  
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Synthesis of FITC-Sq (40) 
 
 
 
To a solution of 5 (0.040 g, 0.000103 mol) in dry DMF (2 ml) NaH (0.003 
g, 0.000103 mol) was added and stirred at room temperature for 3 h. 
Then FITC (0.041 g, 0.000103 mol) was added and the reaction was 
stirred in the dark at room temperature for 72 h. Then the volatiles 
were removed under reduced pressure affording 40 without any further 
purification 
 
1H-NMR: (CDCl3, 300 MHz): δ(ppm)= 6.50-7.20 (m, 9H); 5.00-5.23 (m, 
5H); 4.55 (bs, 1H); 4.10 (t, J=7.1 Hz, 2H); 1.72-2.19 (m, 20H); 1.65 (s, 
3H); 1.57 (bs, 15H). ESI-MS: m/z 775.7 [M-2]+. 
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Biology 
 
Stability of conjugates 8-11a in serum 
 
Incubation in human serum was performed at 37°C with a final 
concentration of NAs of 0.33 mg/mL. Aliquots (60-80 µL) were removed 
after 48 h of incubation. After addition of 0.8 mL of acetonitrile, the 
aliquots were centrifuged and the solution was analyzed. All the tests 
were repeated thrice.  
The chemical stability of our conjugates was determined by HPLC 
analysis: samples in a range of 5-15 μg of the compounds were injected 
into a LiChrospher 100 RP 18e (4.6 × 250 mm, 5 μm) equipped with a 
C18 guard column. The column was eluted with acetonitrile / water 
(40:60 and, after 5 min, a linear gradient to 100% acetonitrile, 35 min) 
at flow rate of1 ml/min, and the column effluent was detected at λ = 227 
nm for compounds 8a and 10a and at λ = 217 nm for 9a and 10a. The 
assay was linear over the tested concentration range (1–50 μg as 
paclitaxel, podophyllotoxin, camptothecin and epothilone A). Eluted 
peaks were also characterized using a Waters HPLC-MS Micromass ZQ 
with ESI detector, eluting the column with methanol and 0.05% 
trifluoroacetic acid in water, with the same gradient as described above. 
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Cell culture and fluorescence microscopy 
 
Human lung carcinoma cell line A549 (CCL-185; American Type Culture 
Collection, Rockville, MD, USA) was grown in minimal essential medium 
with Earle’s (E-MEM), supplemented with 10% fetal bovine serum 
(Hyclone Europe, Oud-Beijerland, Holland), 2 mM L-glutamine, 100 
U/mL penicillin, and non-essential amino acids. Cells were maintained 
at 37°C in a humidified atmosphere at 5% CO2. To test the ability of 
squalene bioconjugated to affect microtubule cytoskeleton, A549 cells 
(50000 cell/ml) were seeded on glass coverslips and grown in control 
medium. After 24 h, cells were incubated for 1 h with 200 μg/ml of the 
squalene bioconjugated, or with equal concentration of the parent 
compounds (paclitaxel, epothilone-A, podophyllotoxin). Cells were fixed 
and permeabilized for 6 min with methanol at -20°C, washed with PBS, 
and blocked in PBS+5% bovine serum albumin (BSA) for 15 min at room 
temperature. To localize tubulin, the cells were incubated with 
monoclonal anti-α-tubulin antibody (clone B-5–1–2, Sigma–Aldrich, St. 
Louis, MO) 1:500 in PBS for 1 h at 37°C. We used goat anti-mouse Alexa 
Fluor568 (Molecular Probes, Eugene, OR) 1:1000 in PBS+1% BSA for 45 
min at 37°C as secondary antibodies. Nuclei staining was performed by 
incubation with DAPI (0.25 μg/mL in PBS) for 15 minutes at room 
temperature. The coverslips were mounted in Mowiol (Calbiochem, San 
Diego, CA)-DABCO (Sigma–Aldrich) and examined with a Zeiss Axiovert 
200 microscope equipped with a 63x Neofluor lens (Zeiss, Oberkochen, 
Germany). 
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Cytotoxicity assay (MCF-7 cell line) 
 
Cytotoxicity was evaluated by incubating the cells with different 
concentrations of nanoassemblies for 48 h at 37 °C/5% CO2. To evaluate 
the activity of nanosuspensions after reduction of disulfide bonds, 
dithiotrithreitol was added to reach a 10 mM concentration and samples 
(at a 1 mM concentration) were incubated for 1h at 37°C. For 
comparison purposes, Paclitaxel, Podophyllotoxin , Camptothecin and 
Epothilone A were used as a control. 
MCF-7 cells (25000/well) were cultured in RPMI 1640 supplemented 
with 10% fetal calf serum, 50 U/mL penicillin, 50 μg/mL streptomycin 
and 2 mM L-glutamine. The cytotoxicity of drugs and drug-squalene NAs 
was determined using sulforhodamine B (SRB) assay essentially as 
described by Voigt[164]. MCF-7 cells were seeded at a density of 25×103 
cells/well in a 96 well plate and incubated for 24 h. Then various 
concentrations of drug-squalene NAs were added to the medium. After 
48 h, the cell viability was determined by the SRB assay: the medium 
was removed and cells were fixed with trichloroacetic acid, washed and 
stained with SRB (100 μl/well SRB 0,057% w/v in acetic acid 1% v/v). 
After the washings, 200 μl/well of 10 mM Tris base (pH 10.5) were 
added and, after 30 min, the absorbance was measured (λ = 492 nm) 
using a 96-well plate reader (Titertek Multiskan PLUS MKII). The 
survival percentages were calculated using the following formula: 
Survival % = (A492 nm for the treated cells/A492 nm for the control 
cells) ×100%. The experiment was repeated thrice in triplicate for each 
concentration of the tested compounds. 
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Cytotoxicity assay (A549 cell line) 
 
A549 cell line was maintained in RPMI1640 (Lonza) with the addition 
of 10% FBS (fetal bovine serum) and 2 mM L-Glutamine (Lonza) in a 
Heraeus CO2 Auto-Zero incubator at 37°C in a humidified atmosphere 
of 5% (v/v) CO2 in air. 
Cytotoxic assays on A549 cells were performed in tissue-treated 96 well 
plates (Falcon). In particular, cells were trypsinized, washed with PBS 
(Lonza) and plated in 96 well plates at a concentration of 15,000 
cells/ml in a total volume of 100 µl. 72 h later cells were treated with 
100 µl of different chemical compounds (2X solutions were prepared) at 
various concentrations, diluted in colture medium. Cell survival was 
assessed 96 h after treatment by MTS assay. MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) in the presence of phenazinemethosulfate (PMS), 
produces a formazan product that has an absorbance (Abs) maximum at 
490-500 nm in phosphate-buffered saline. The reading of absorbance at 
540 nm was performed by using a reader plate (TECAN).  
The “% Ctr” was calculated for each dose as: 
 
%Ctr =
Abs in "x" dose treated sample
Abs in Ctr sample
 ∗ 100 
 
For each dose 5 replicates were performed and dose/response curves 
were plotted as mean± standard deviation for each dose. IC50 values 
were extrapolated from the dose-response curves. 
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Cell cultures and live cell imaging  
 
Human lung carcinoma cell line A549 (CCL-185; American Type Culture 
Collection, Rockville, MD, USA) was grown in minimal essential medium 
with Earle’s (E-MEM), supplemented with 10% fetal bovine serum 
(Hyclone Europe, Oud-Beijerland, Holland), 2 mM l-glutamine, 100 U/ml 
penicillin, and non-essential amino acids. Cells were maintained at 37 °C 
in a humidified atmosphere at 5% CO2.  
For the internalization assay, A549 cells (50000 cell/well) were seeded 
onto glass coverslips in 6-well tissue culture plates, and the day after 
cells were incubated for different time with mixture of PTX-Sq and FITC-
Sq at two different molar ratios: 
 
 Mixture B (PTX-Sq/FITC-Sq 10:1): 13.8 μM 
 Mixture D (PTX-Sq/FITC-Sq 30:1): 4.6 μM 
 
After defined times (10, 30 and 60 minutes), cells were washed in PBS 
and some random images per plate were captured, in both phase 
contrast and fluorescence, using an Axiovert 200M microscope (Zeiss, 
Oberkochen, Germany). Immediately after, cells were fixed with 4% 
paraformaldehyde, and then cells were incubated with phalloidin-
tetramethylrhodamine B isothiocyanate and 4′,6-diamidino-2-
phenylindole dihydrochloride (Sigma-Aldrich). The coverslips were 
mounted in Mowiol

 (Calbiochem, San Diego, CA)–DABCO (Sigma-
Aldrich) and examined with the Axiovert 200M microscope (Zeiss).  
Cultures were washed once in PBS and transferred to a live cell imaging 
workstation composed of an inverted microscope (Axiovert 200, Carl 
Zeiss) equipped with a Plan neofluar 63x/1.25 NA oil objective, and and 
images were collected every minute with a cooled camera (Axiocam 
HRM Rev. 2, Carl Zeiss), for a total time of 20 minutes. 
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